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At the end of the 1990s it was apparent that a universal meningococcal vaccine was beyond the 
reach of conventional vaccinology…Therefore, the complete genome sequence of [Neisseria 
meningitidis] was determined… 
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Neisseria meningitidis, also known as the meningococcus, is a gram negative diplococcus 
that inhabits the human nasopharynx (Rosenstein et al., 2001).  N. meningitidis is arguably the 
worldwide leading cause of bacterial meningitis which is a sudden and life threatening disease.  
Even with proper treatment 10% of all cases are fatal, with an additional 10% sequelae. 
Since the early 1900s physicians have been attempting to design antisera and vaccines to 
combat the meningococcus (Bilukha & Rosenstein, 2005; Flexner, 1913; Goldschneider et al., 
1969a; Goldschneider et al., 1969b; Gotschlich et al., 1969a; Gotschlich et al., 1969b; Gotschlich 
et al., 1969c).  N. meningitidis can also be combated with antibiotics, but many powerful drugs 
are meeting resistance (e.g.,Wu et al., 2009). 
N. meningitidis is surveyed worldwide using many profiling systems.  One of the most widely 
used includes serogrouping assays, which determine the type of polysaccharide capsule 
enclosing the isolate (Mothershed et al., 2004; Popovic & Ajello, 2003).  However to better study 
the population structure of N. meningitidis, scientists use a system called multilocus sequence 
typing (MLST).  MLST is a molecular profiling system that uses seven conserved loci.  These loci 
are sequenced, and their allelic variants are determined as allele calls.  The specific combination 
of allele calls yields the sequence type (ST) which is the profile of the isolate.  STs can be 
compared and tracked to survey isolates worldwide.  Fortunately there is a database of STs 
called PubMLST, with which a scientist can use to compare their sequences with and determine 
their own ST or declare novel alleles and STs (Jolley et al., 2004).  However unfortunately until 
2009, the bioinformatics package available for meningococcal reference labs was not user 
friendly, was not maintained by the original developers, and was out of date (Chan & Ventress, 




In chapter 2 of this thesis, I describe how I created a suite of tools called the Meningococcus 
Genome Informatics Platform (MGIP) to analyze MLST data.  MGIP is about five times faster and 
is more flexible than its predecessor, is user friendly, and is becoming the gold standard in MLST 
analysis.  MGIP has had several advances since its release in 2009 including the expansion to 
other loci and other organisms.  In fact as detailed in chapter 3, the CDC Influenza Division has 
adapted MGIP into their own typing tool called the Influenza Genomics Platform (InGen).  InGen 
will be used to survey influenza worldwide.  State health laboratories will be given InGen in 
exchange for real-time data from across the nation.  InGen has been demonstrated to the 
Egyptian government and has been the subject at a recent talk at an international influenza 
meeting in China.  MGIP has been accepted by CDC as its main analysis tool for MLST.  As such 
the way has been paved for worldwide acceptance of MGIP and InGen for meningococcal and 
influenza surveillance. 
To better understand N. meningitidis a whole genome approach has been adopted at CDC.  
There are many lingering questions that are best suited for whole genome analysis.  For 
example, only some strains of N. meningitidis cause disease whereas the great majority of all 
strains are not invasive.  The trigger that causes strains to switch from virulent to carriage or vice 
versa remains a subject of exploration.  Another question that could be answered by genomics 
pertains to the meningococcal capsule.  Most often the capsule type can be identified, but what 
causes it to become nongroupable, i.e. unable to be classified into exactly one capsule type?  
Whole genome analyses can address this question. 
Before these questions can be answered whole genomes must be able to be sequenced and 
characterized.  Since 2005, it has been possible to sequence whole genomes in less than a day 
(Margulies et al., 2005).  However, to correctly assemble and annotate the entire genome is a 




computational genomics pipeline (CG-Pipeline).  CG-Pipeline takes 454 pyrosequencing data files 
as input, assembles sequencing reads, predicts features (e.g. coding sequences), and annotates 
them.  Since its inception in June 2010, several prominent institutions have begun using it 
including CDC, Georgia Institute of Technology, Pacific Biosciences, and the National Biodefenses 
and Countermeasures Center (NBACC) under the Department of Defense.  In addition it is quite 
possible that other major institutions have begun using CG-Pipeline but have understandably 
not discussed their projects with our team.  CG-Pipeline is discussed in chapters 4 and 5. 
The output of CG-Pipeline is a well-annotated but plaintext GenBank file.  To properly 
visualize, characterize, and compare each of these genomes, we developed an online 
comparative database called Neisseria Base (NBase).  NBase is the fitting second half of CG-
Pipeline in that it is a platform suitable for the storage and analysis of all meningococcal 
genomes.  Currently NBase is capable of comparing multiple genomes to yield differences 
between them and allows a layman scientist to navigate through any of nearly 30 
meningococcal genomes hosted on the database.  NBase is described in chapter 5.   
With the combination of CG-Pipeline and NBase, it became feasible to study meningococcal 
genomes by sequencing and characterizing them and to ask certain questions.  In chapter 6, I 
questioned why some meningococcal isolates are virulent while the rest are asymptomatically 
carried.  This has been an open question for decades and has only been addressed on a genomic 
level in the last eight years with little success (Hotopp et al., 2006; Perrin et al., 2002; Schoen et 
al., 2008; Snyder & Saunders, 2006; Stabler & Hinds, 2006; Stabler et al., 2005).  To address this 
question, I compared eight virulent genomes against three carriage.  In the results, I was able to 
uncover 801 single nucleotide polymorphisms (SNPs) in the N. meningitidis genome that 
distinguish virulent from carriage genomes.  Furthermore, I was able to uncover 113 genes that 




genes to ten genes that are involved in virulence.  These genes have been offered to the 
scientific community for further investigation.  These SNPs and genes represent the only 
unambiguous genomic distinction between virulent and carried isolates of N. meningitidis 
known at this time. 
Another question that I was able to address was what makes some isolates nongroupable?  
In chapter 7, I compared a nongroupable isolate against reference genomes to speculate on a 
genomic level why its phenotype is nongroupable.  To this end, I developed two methodologies.  
One, I mapped all 454 pyrosequencing reads of this isolate to a reference genome to develop a 
profile.  This profile is much more comprehensive than any other current genetic profile and 
allowed me to determine which reference genome was most related to my own query genome.  
The second method was to ascertain exact recombination points.  The genomic basis of this 
isolate’s nongroupability is most likely due to recombination, and so I found the exact places of 
recombination.  The gene most likely responsible for nongroupability was found to be part of a 
recombination event and is elaborated upon in chapter 7.  This study would not have been 







INTRODUCTION AND LITERATURE REVIEW 
HISTORY OF NEISSERIA MENINGITIDIS, THE MENINGOCOCCUS 
The meningococcus is a gram-negative encapsulated diplococcus that lives in the human 
nasopharynx (Rosenstein et al., 2001).  Sometimes it causes acute invasive disease but usually it 
is carried as a harmless commensal. 
The origin of N. meningitidis seems to be very recent.  Most believe that the disease, and by 
extension the meningococcus, first made its appearance in 1805 in France and 1806 in the 
United States (Danielson & Mann, 1806; Vieusseux, 1806).  The physician Anton Weichselbaum 
first isolated the bacterium in 1887 and dubbed it “epidemic cerebrospinal meningitidis” 
(Weichselbaum, 1887).  After it was isolated, advances came more often in the late 19th century 
and early 20th century such as the ability to differentiate it from N. gonorrhoeae, identifying its 
commensal state, its isolation from the human throat, and even the first antisera (Cartwright, 
2006; de Souza & Seguro, 2008).  Indeed, the mortality rate in the early 20th century went from 
about 70% to 25% as a result of the antisera (Flexner, 1913). 
Development of a vaccine occurred in the early 20th century where heat-killed meningococci 
were delivered to a group of American medical students, nurses, and their close contacts 
(Cartwright, 2006).  Next, 4700 US soldiers were given the vaccine and it was shown that the 
number of disease cases was significantly different between immunized and unimmunized 
soldiers.   
Starting in the 1960s, vaccine development began in the US to produce vaccines against the 




disease cases in the world (Goldschneider et al., 1969a; Goldschneider et al., 1969b; Gotschlich 
et al., 1969a; Gotschlich et al., 1969b; Gotschlich et al., 1969c).  It would not be until 2000 that a 
different technique called reverse vaccinology would be applied to find a vaccine against 
serogroup B (Rappuoli, 2000), and it would not be until 2008 that a vaccine would be in clinical 
trials under Novartis’s auspices (Rinaudo et al., 2009). 
DISEASE 
N. meningitidis is named as such because it causes meningitis, the inflammation of the 
meninges.  Meningococcal disease is characterized by purulent meningitis, with a sudden onset 
of headache, fever, and stiffness of neck (Rosenstein et al., 2001).  Occasionally, meningococci 
can reside in the bloodstream causing meningococcal sepsis, which is also known as 
meningococcemia.  N. meningitidis, especially serogroup Y, can also occasionally cause 
pneumonia or other respiratory problems (Racoosin et al., 1998). 
Of those who get meningococcal disease, about 10% die, and of those, about 15% develop 
long-term sequelae such as deafness, cognitive impairment, and other central nervous system 
complications  (Palmgren, 2009).  The current recommendation for those at risk for 
meningococcal disease is to give regiments of the antibiotics rifampin, ciprofloxacin, and 
ceftriaxone (Bilukha & Rosenstein, 2005).  For those who need immediate treatment, 
ciprofloxacin is recommended but there are signs of increasing resistance (Wu et al., 2009).    
Ultimately the most effective way to address meningococcal disease is to confer immunity 
using vaccines.  Current vaccines target the polysaccharide capsule, which ironically protects the 
bacterium from opsinophagocytosis by the immune system (Campagne et al., 2000; Miller et al., 
2001; Zombre et al., 2007) .  Current vaccines can target the polysaccharide capsule of 
serogroups A, C, W135, and Y.  However, the capsule from serogroup B cannot be targeted 




found in the human brain (Finne et al., 1983).  Therefore a conventional vaccine against the 
polysaccharide capsule of serogroup B would either be ineffective or would induce 
autoimmunity. 
POPULATION STRUCTURE 
The population structure of N. meningitidis can be described in several ways.  The earliest 
methods of typing involved using antisera to classify them, which evolved into the 
aforementioned serogroup classification.  The known serogroups are A, B, C, D, 29E (Z’), H, I, K, 
L, W135, X, Y, and Z (Ashton et al., 1983).  However, many experimentalists are leaning to 
believe that serogroup D exists merely as an extension of serogroup C antisera and therefore 
there are 12, not 13, known serogroups (Popovic & Ajello, 2003; personal communication, 
Jennifer Dolan Thomas).  The serogroups that are known to be invasive are A, B, C, W135, X, and 
Y.  Of those that are invasive, serogroups B and C predominate in the industrialized world 
(Figure 1.1).  Serogroup A prevails in Africa and Asia.  Serogrouping is very fundamental and is in 
wide use today. 
With newer technologies in protein and DNA analysis, typing methods became better in 
resolution.  One notable method of typing, called multilocus enzyme electrophoresis (MLEE), 
screens for certain cytoplasmic enzymes and determines its electromorphic profile through a gel 
(Caugant et al., 1986).  Each different combination of electromorphs yields an electrophoretic 
type (ET).  MLEE has been mostly abandoned however for a new technique called multilocus 
sequence typing (MLST) (Maiden et al., 1998).  Using MLST, a scientist sequences the DNA of 
seven loci of housekeeping genes, give or take a few loci depending on the species (Table 1.1).  
The sequence of each locus yields an allele, and the combination of all alleles determines the 
isolate’s sequence type (ST), which is its profile.  In MLST, individual STs are assigned to clonal 




common.  MLST has many advantages over MLEE: all ETs can be directly translated to STs; data 
used for MLST can be transferred electronically; the resolution is better due to digital data 
rather than using a gel and also due to the redundancy of the genetic code (nucleotide 
sequences are more discriminating than amino acid sequences); and its results are easily 
comparable in that it is a standardized typing scheme whereas the proteins used in MLEE varied 
between laboratories.  One might argue that using housekeeping genes to detect population 
structure would not yield the desired resolution; however, Neisseria undergoes so many 
recombination events that housekeeping genes are the best way to describe the population 
structure in lieu of entire genomes (Holmes et al., 1999; Jolley et al., 2005).  For all of these 





Table 1.1. The seven loci used in MLST for N. meningitidis. 
Locus  Description  
abcZ  putative ABC transporter  
adk  adenylate kinase  
aroE  shikimate dehydrogenase  
fumC  fumarate hydratase  
gdh glucose-6-phosphate dehydrogenase  
pdhC  pyruvate dehydrogenase subunit  
pgm phosphoglucomutase  
 
 
Comparative analysis of clonal complexes uncovered by MLST helps to describe the 
phylogenetic origins of each meningococcal isolate and also lends insight into trends.  One trend 
for example is that nearly all virulence caused by N. meningitidis is caused by relatively few CCs.  
Another trend is that each CC can be correlated with a serogroup (Table 1.2).  
 
 
Table 1.2.  Common virulent STs and their serogroups, adapted from (Yazdankhah et al., 2004).  Major 
serogroup/CC correlation percentages have been bolded. 







A B C Y W135 NG
b 
ST-11 52 (20-135) 0% 11% 81% 0% 6% 3% 
ST-23 0.2 (0.1-0.7) 0% 10% 0% 56% 3% 31% 
ST-32 0.9 (0.4-2.2) 0% 82% 6% 3% 0% 10% 
ST-35 0.3 (0.1-1.1) 4% 50% 0% 4% 0% 42% 
ST-162 0.8 (0.4-1.18) 6% 82% 0% 0% 6% 6% 
ST-269 6.1 (0.5-12.8) 0% 86% 0% 5% 0% 9% 
ST-41/44 1.1 (0.5-2.3) 0% 78% 2% 2% 0% 17% 
a







Most epidemiological studies focus around MLST (Didelot et al., 2009; Holmes et al., 1999; 
Maiden et al., 1998).  However, some protein-based typing systems are still being used, 
especially subtyping.  In meningococcal subtyping, PorA, PorB, and FetA are assessed for more 
resolution of the population structure.  PorA and PorB are porins, which allow small molecules 
to pass across the outer membrane.  FetA (previously, FrpB) is a siderophore that is expressed 
when iron concentrations are low (Beucher & Sparling, 1995).  Variants on the PorB protein 
sequence (and more recently, the DNA sequence) are used to identify the serotype.  Variants on 
the PorA sequence yield a serosubtype.  Standard subtyping notation is given by serogroup: 
PorA: FetA: ST (CC) (Jolley et al., 2007).  One example of a profile designation would be 
B:P1.19,15:F5-1:ST-33(cc32) for  serogroup B, PorA type P1.19, FetA type F5-1, and 
ST-33 with ST-33 belonging to clonal complex ST-32.  Because the PorB sequence is more time-






Figure 1.1.  Global distribution of meningococcal disease.  The distribution of the various serogroups of 
meningococci is indicated by the appropriate letters.  Adapted from (Tikhomirov et al., 1997). 
INVASIVE OR CARRIAGE? 
Most often N. meningitidis can be found asymptomatically carried in the back of the throat 
(Claus et al., 2005; Dolan-Livengood et al., 2003).  However it has been noted that there are a 
few hypervirulent lineages that are found to cause disease.  Many studies have tried to find the 
underlying genetic cause (Bille et al., 2005; Hotopp et al., 2006; Perrin et al., 2002; Schoen et al., 
2008; Snyder & Saunders, 2006; Stabler & Hinds, 2006; Stabler et al., 2005).  However, the best 
results from these studies have been shown support against them, and it is still an open-ended 
question.  There are many hypotheses as to which factor is the genetic switch from invasive to 
carriage.  For example, many believe the answer to be related to pili (Nassif et al., 1997; 
Stephens et al., 1983), and others believe it the switch is related to evading the immune system 
with proteins such as IgA protease (Lin et al., 1997; Mistry & Stockley, 2006).  While the genetic 





MOLECULAR ASPECTS OF MENINGOCOCCUS 
DNA 
Sequencing of the meningococcal genome began with the strains Z2491 (Parkhill et al., 
2000) and MC58 (Tettelin et al., 2000).  Other genomes have been published since then (Table 
1.3).  In my collaboration with the CDC Meningitis Laboratory we have sequenced several 
genomes and several are still in the process of being made public (Table 1.3).  Some basic facts 
have arisen as a result of these sequencing projects.  The meningococcal genome is about 2.15 
Mb; the GC content is, on average, higher than 51%; and the number of genes on average per 





Table 1.3.  Completed known genomes at the time of this dissertation.   












M20918 Iowa, USA 2009 A Invasive 4789 5 N/A 
M13220 Philippines 2005 A Invasive 7 5 20519285 
M18575 Burkina Faso 2003 A Invasive 2859 5 20519285 
Z2491 Gambia 1983 A Invasive 4 4 10761919 
M17277 Maryland, USA 2006 NG Carriage 5916 41/44 N/A 
M16207 North Dakota, USA 2007 B Invasive 162 162 N/A 
M17094 Minnesota, USA 2008 B (C) Carriage 32 32 N/A 
MC58 Gloucester, UK 1985 B Invasive 74 32 10710307 
M10699 Oregon, USA 2003 B Invasive 32 32 20519285 
M5178 Oregon, USA 1998 B Invasive 32 32 20519285 
053442 Anhui province, China 2003 C Invasive 4821 4821 18031983 
8013 France 1989 C Invasive 177 18 19818133 
FAM18 North Carolina, USA 1980s C Invasive 11 11 17305430 
M15141 New York, USA 2006 C Invasive 11 11 20519285 
α14 Bavaria, Germany 1999-2000 NG-cnl Carriage 53 53 18305155 
M17062 Minnesota, USA 2008 NG Carriage 198 198 N/A 
M15293 Georgia, USA 2006 NG (B)
 
Invasive 32 32 20519285 
M16917 Illinois, USA 2007 NG
 
Invasie 11 11 N/A 
α153 Bavaria, Germany 1999-2000 29 Carriage 60 60 18305155 
α275 Bavaria, Germany 1999-2000 W135 Carriage 22 22 18305155 
M13519 New York, USA 2005 W135 (C) Invasive 11 11 N/A 
M17661 Michigan, USA 2008 W135 (C) Invaive 11 11 N/A 
M18774 Florida, USA 2009 W135 Invasive 11 11 N/A 
NM9261 urkina Faso 2002 W135 Invasive 11 11 20519285 
M11791 New York, USA 2003 Y Invasive 23 23 N/A 
M14900 Oregon, USA 2006 Y Invasive 1625 23 N/A 
M20899 California, USA 2009 Y Invasive 1624 167 N/A 
a
 Origins are based on literature searches for each genome or based on unpublished notes at Centers for Disease 
Control and Prevention. 
b
 Serogroup.  Sgs are defined as a result of the SASG test, and if PCR had a differing result its resulting serogroup 
is in parentheses (Mothershed et al., 2004).  cnl: the capsule locus is nonexistent and no capsule is expressed. 
c
 Sequence Type (ST), Clonal Complex (CC). 
d





Before these genomes had been completed, it was well known that many genes were 
shared using DNA uptake sequences (DUSs) as markers for neisserial origin (Goodman & Scocca, 
1988; Smith et al., 1999).  Nearly 2000 of these occur in each meningococcal genome, and they 
function to incorporate flanking sequences through homologous recombination (Linz et al., 
2000).  Another avenue of inducing homologous recombination is through insertion sequence 
(IS) elements (Mahillon & Chandler, 1998).  IS elements in the meningococcal genome are on 
the order of 1kb and code for transposase activity.  Pairs of IS elements can therefore act as a 
cassette and transpose flanking genomic regions to cause whole genomic rearrangements 
(Kawai et al., 2006).  Furthermore, simple repeat sequences such as dRS3 have been correlated 
with inversions (Schoen et al., 2008). 
PROTEIN 
Many proteins are important foci for epidemiological, mechanistic, and immunological 
studies.  Epidemiological studies are as described in the previous Population Structure section.   
Mechanistic studies give insight into how the meningococcus colonizes and invades a human 
host.  The line between colonization and invasion is blurred.  Many adhesins such as pili are 
known to aid in epithelial adhesion between N. meningitidis and the human epithelium.  In 
other words, these proteins are meant to help in colonization and not invasion.  Seemingly by 
accident in symptomatic patients, these proteins begin helping in invasion.  It is well-known that 
pili are important for invasion (McGee et al., 1983).  So therefore, a major question in invasion 
mechanism studies is, when is a protein considered invasive or just a way to inhabit a human 
host peacefully (Meyers et al., 2003; Schoen et al., 2008)?  This question has not been fully 





Also studies elucidate how the meningococcus interacts with the immune system.  One 
benefit of understanding this interaction would presumably be to make an all-inclusive 
meningococcal vaccine—only four out of the major five virulent serogroups are targeted by 
vaccines today, and ideally targeting all possibly-virulent serogroups is the goal.  Therefore 
targeting a protein or set of proteins would be the best way to make a universal vaccine.  Many 
proteins especially Opa and PorB (Estabrook et al., 2004), PorA (Jarva et al., 2005), factor H-
binding protein (fHBP) (Fletcher et al., 2004; Madico et al., 2006; Masignani et al., 2003), NadA 
(Litt et al., 2004), and NHBA (previously GNA2132) (Lucidarme et al., 2009) have been known to 
elicit an immune response.   
Creating a universal vaccine was jump-started by a method called reverse vaccinology where 
a genome – the entire set of genes an organism can make – can be analyzed for vaccine 
potential (Rappuoli, 2001).  The best qualities of a vaccine protein target are to be expressed 
outside the cell, to be conserved and not variable, and to be visible to the immune system (Pizza 
et al., 2000).   
Currently there are two major companies proceeding with the creation of a vaccine.  
Novartis is creating a vaccine based on five antigens, based on their reverse-vaccinology studies 
(Jacobsson et al., 2009).  These genome-derived neisserial antigens (GNAs) are a fusion of fHBP 
variant 1 and GNA2091, a fusion of NHBA and GNA1030, and NadA.  The protein fHBP is a 
cofactor of factor I and aids the bacterium in avoiding complement-based attack by the immune 
system (Schneider et al., 2006).  NHBA is not well characterized but has some relevance to 
serum resistance, binds to heparin, and is a possible adhesin (Lucidarme et al., 2009; Serruto et 
al., 2010).  It seems that GNA2091 plays a role in stress responses (Seib et al., 2010).  GNA1030 
has not been characterized much yet but it seems as though efforts into understanding it are 




epithelial cells (Capecchi et al., 2005).  A sixth ingredient is the outer membrane component 
PorA P1.7-2,4, which was a specific protein found in the MeNZB campaign against a 14-year 
epidemic in New Zealand (Sexton et al., 2004a; Sexton et al., 2004b).  By having a diverse 
accompaniment of proteins, this vaccine will not allow for many escape mutants and will be 
effective in preventing meningococcal disease. 
Another company Wyeth is approaching the problem by using one protein fHBP (Fletcher et 
al., 2004; Masignani et al., 2003).  The population structure of fHBP has been analyzed without 
regard to MLST or other typing methods (Murphy et al., 2009).  In this way, most of the different 
variants of fHBP could be incorporated into the vaccine and therefore would be protective 
against most isolates.  All isolates contain fHBP, and if the vaccine contains most variants of the 
protein, then it will prevent meningococcal disease.   
There have been other vaccine attempts (Sadarangani & Pollard, 2010), many of them 
successful, but as of today only the Novartis and Wyeth vaccines are coming close to being 
universal.  Presently, the most effective vaccines are those against the capsules of isolates 
belonging to serogroups A, C, Y, and W135 (Popovic & Ajello, 2003). 
CAPSULE 
The meningococcus has a group II polysaccharide capsule, which helps protect it from the 
immune system and from the environment (Costerton et al., 1981; Swain & Martin, 2007).  
Meningococcal capsules are composed of polysaccharides and contain 95% water (think of a 
very watery gelatin mix).  Therefore if it is thick enough, it is difficult for a phagocyte to ingest it 
or to destroy it with a lysosome.  In addition it is protective against the environment.  
Meningococci do not live anywhere except in the human nasopharynx, but there is some 
assumed time that it must spend outside of the host before reaching the next host.  The capsule 




There are 13 serogroups: A, B, C, D, 29E, H, I, K, L, W135, X, Y, and Z (Ashton et al., 1983).  
However, serogroup D might exist merely as an artifact of serogrouping assays (Popovic & 
Ajello, 2003; personal communication, Jennifer Dolan Thomas).  Each serogroup differs in its 
molecular composition (Table 1.4).  The differences between each serogroup include its choice 
of sugar monomer derivative; modifications such as acetyl groups; and linkages between sugars 





Table 1.4.  Molecular composition of serogroups.   
Serogroup D has been removed, as there is no chemical or genetic data available and also because it likely exists 
merely as an artifact of nonspecific antisera to serogroup C.  Adapted from (Dolan-Livengood et al., 2003; Frosch & 
Vogel, 2006). 
Serogroup Structure Genes 
A →6)-α-D-ManpNAc-(1→OPO3→ sacA-sacD 
B →8)-α-D-Neup5Ac-(2→ synA-synD 
C →9)-α-D-Neup5Ac-(2→ synA-synC, synE 
29E →3)-α-D-GalpNAc-(1→7)- β-D-KDOp-(2→ cap29eA-cap29eH 
H →4)-α-D-Galp-(1→2)-Gro-(-3→OPO3→  
I →4)-α-L-GulpNAcA-(1→3)- β-D-ManpNAcA(→  
K →3)- β-D-ManpNAcA-(1→4)- β-D-ManpNAcA-(1→  
L →3)-β -D-GlcpNAc-(1→3)- β-D-GlcpNAc-(1→3)-α-D-
GlcpNAc-(1→OPO3)→ 
lbcA-lbcC 
W135 →4)-α-D-Neup5Ac-α-(2→6)-α-D-Gal-(1 → synA-synC, synG 
X →4)-α-D-GlcpNAc-(1→OPO3 → xcbA-xcbC 
Y →4)-α -D- Neup5Ac-α-(2→6)-α-D-Glc-(1→ synA-synC, synF 
Z →3)-α-D-GalpNAc-(1→1)-Gro-(3→OPO3→ capZA-D 
 
 
The capsule is genetically coded by the cps complex and can be divided into regions D’, E, C, 
A, D, and B (Frosch et al., 1989; Tzeng et al., 2005).  More important though are the operons at 
regions C and A which respectively code for transport and synthesis of the capsule.  They are 
separated by a short intergenic region 134 nt long (Swartley et al., 1997).  The operon at region 
C codes for genes ctrA-ctrD which code for an ABC transporter.  This transporter is also aided by 
the genes ctrE and ctrF in region B (Tzeng et al., 2005) and also ctrG (Hobb et al., 2010).  
Synthesis of the capsule is performed by region A which is an operon that contains synA-synD 
(Swartley et al., 1996).  The first genes synA-synC are responsible for creating enzymes that 
manufacture the monomer sugar.  The last gene is a polymerase and is responsible for linkages.  
The synA-synC genes are homologous between serogroups that share the same sugar (e.g. 
serogroup B and C have the same modified sialic acid), but synD is specific to each serogroup.  
Because of the diversity of synD genes and the differences in sugars, the naming convention 




convention is by serogroup and so in serogroup A the genes are named sacA-sacD (Syn: mynA-
mynD), and in serogroup C the genes are named synA-synC and synE (syn: siaA-siaDC).  Because 
different serogroups have wholly different sugars, the synD genes are not considered alleles, but 
different genes.  For consistency throughout this thesis, save chapter 8, the synthesis genes will 
be named synA-synD. 
As a result of the plasticity of the meningococcal genome, a phenomenon called capsule 
switching can occur (Swartley et al., 1997).  Whole sections of the genome, on average 1.1 kb 
(Jolley et al., 2005), can be homologously recombined.  Consequently, if a section of the capsule 
synthesis region is recombined then the serogroup can switch.  This phenomenon was first 
discovered in 1997 (Swartley et al., 1997) and confirmed in 2000 (Vogel et al., 2000).  Because 
serogroup and ST can be correlated, it can now be said that when an isolate belongs to a 
serogroup not correlated with an ST, there is evidence of capsule switching (Harrison et al., 
2010).  It occurs more often than expected; 4.3% of all isolates were determined to have arisen 
as a result of capsule switching in a 2010 study (Harrison et al., 2010). 
Another phenomenon related to the capsule is nongroupability.  An isolate is considered 
nongroupable (NG) if it has no capsule, if it belongs to more than one serogroup, or if the isolate 
is untestable, i.e. it cannot be placed in any one group (Mothershed et al., 2004).  The gold 
standard to test for serogroup is through the slide agglutination serogrouping (SASG) test.  
Isolates are placed into separate whole-cell ELISA tests, one for each serogroup.  If no reaction 
takes place then it belongs to no serogroup, and likely, placing it into human serum will kill the 
cells due to the immune system (Dolan-Livengood et al., 2003).  If the isolate agglutinates in the 
presence of saline and not antibodies then it is an autoagglutinator and is nongroupable.  If the 
SASG test results in more than one positive, then the isolate is nongroupable because it belongs 




been targeted for standard primers for qualitative PCR.  Each serogroup’s set of primers is used 
on an isolate, and if there is a positive result in the PCR, it is positive for that serogroup.  The 
PCR test adds quality to serogrouping but also adds another phenomenon where the SASG test 
and PCR test disagree (Mothershed et al., 2004).  If the results disagree, it is called a discrepant 
result (DR). 
Several vaccines target polysaccharide capsules.  The two most notable polysaccharide 
vaccines are tetravalent for serogroups A, C, W135, and Y.  The first, MPSV4, is composed only 
of the polysaccharide, purified from meningococcal lysate.  It is still widely used for children 2-
10 years of age and persons over 55 (Bilukha & Rosenstein, 2005).  The other notable 
tetravalent vaccine, MCV4, is licensed for people 20-55 years old and is recommended for those 
11-55 (Bilukha & Rosenstein, 2005).  MCV4 is a conjugate vaccine composed of the 4 types of 
polysaccharide and diphtheria toxoid.  Conjugate vaccines are theoretically better because they 
induce a T-cell response which creates memory T-cells; however, preliminary data show that 
MPSV4 and MCV4 both provide the same level of immunogenicity (personal communication, 
Jessica MacNeil). 
DESCRIPTION OF THIS THESIS 
This thesis is an answer to many of the questions and problems above.  First, MLST and 
other DNA-based typing methods are cumbersome.  I have devised a platform which will be 
described in chapter 2 that makes DNA-based typing much easier for the experimentalist.  These 
tools, dubbed The Meningococcus Genome Informatics Platflorm (MGIP), are currently being 
used at the Centers for Disease Control and Prevention (CDC) and other world-class laboratories 
for meningococcal surveillance and are replacing the software Sequence Typing Analysis and 
Retrieval System (STARS) (Chan & Ventress, 2001).  In the last year, the CDC Influenza Division 




accompany a new sequence typing method called Small Target Reassortant Screen (STaRS).  
STaRS is used by the Influenza Division to aid in worldwide surveillance of influenza much like 
MLST is used to observe N. meningitidis.  To analyze STaRS data, I created the Influenza 
Genomics Platform (InGen).  I will discuss InGen further in chapter 3. 
Aside from epidemiology, a major question persists in the study of meningococci (Meyers et 
al., 2003).  Why are most strains carried asymptomatically while only a small percentage of the 
population causes acute disease?  N. meningitidis is most frequently found to be 
asymptomatically carried (Maiden & Caugant, 2006).  Carriage studies reveal that about 10% of 
healthy individuals are carriers of N. meningitidis (Claus et al., 2005; Dolan-Livengood et al., 
2003).  Thus, N. meningitdis strains can be phenotyically divided according to their pathogenic 
potential: invasive versus carriage strains.  Invasive strains may be asymptomatically carried for 
some time, but they also have the potential to cause invasive disease.  The vast majority of 
meningococcal meningitis outbreaks are caused by a limited number of invasive strains.  
Carriage strains, on the other hand, are not invasive and thus do not have a large potential to 
cause disease.  Understanding the genomic differences between invasive versus carriage strains 
may provide fundamental insight into the mechanisms of virulence in N. meningitdis.  Although 
this question has not been answered experimentally yet, I have narrowed the search 
considerably as shown in chapter 6.  Owing to the fact that the presence or absence of any gene 
in the meningococcal genome cannot unambiguously determine virulence (Schoen et al., 2008), 
I performed a genome-wide analysis to detect single nucleotide polymorphisms (SNPs).  
However in order to perform whole-genome analyses, a genome assembly annotation pipeline 
had to be developed.  At the time of this thesis proposal in October 2008, only four invasive 
meningococcal genomes had been sequenced (Bentley et al., 2007; Parkhill et al., 2000; Peng et 




studies.  In chapter 4, I describe how I led a team of bioinformaticians to create a genome 
assembly and annotation pipeline called the computational genomics pipeline (CG-Pipeline).  
CG-Pipeline produces annotated genomes from 454 pyrosequencing runs (Margulies et al., 
2005).  Owing to the next-generation technologies and to CG-Pipeline, the time it takes to 
produce an annotated bacterial genome from the nasopharynx has been reduced from years to 
days. 
 Although the final GenBank file outputted from CG-Pipeline can be viewed by a biologist, it 
was a natural next step to produce a genome browser.  This genome browser would be capable 
of interactively navigating through a genome, with added features such as searching.  In chapter 
5, I describe how I led a team of bioinformaticians to produce Neisseria Base (NBase) to achieve 
such a purpose.  
Using these finalized genomes I was able to address another open question: how are some 
isolates nongroupable, and what do they look like on a genetic level?  In chapter 7, I show how 
the cps complex appears on a genetic level in such a genome. 
Therefore this thesis describes how I created a tool to aid in epidemiological surveillance of 
N. meningitidis and influenza; how I created a genome annotation pipeline as the counterpart to 
next-generation sequencing technologies; how I compared several genomes to find markers for 
invasiveness in N. meningitidis which will be targets of future experimental investigation; and 
how I characterized a nongroupable genome.  These studies are currently aiding in public health 







MENINGOCOCCUS GENOME INFORMATICS PLATFORM: A 
SYSTEM FOR ANALYZING MULTILOCUS SEQUENCE TYPING 
DATA 
ABSTRACT  
The Meningococcus Genome Informatics Platform (MGIP) is a suite of computational 
tools for the analysis of multilocus sequence typing (MLST) data, at 
http://mgip.biology.gatech.edu.  MLST is used to generate allelic profiles to characterize strains 
of Neisseria meningitidis, a major cause of bacterial meningitis worldwide.  N. meningitidis 
strains are characterized with MLST as specific sequence types (ST) and clonal complexes (CC) 
based on the DNA sequences at defined loci.  These data are vital to molecular epidemiology 
studies of N. meningitidis, including outbreak investigations and population biology.  MGIP 
analyzes DNA sequence trace files, returns individual allele calls and characterizes the STs and 
CCs.  MGIP represents a substantial advance over existing software in several respects: 1) ease 
of use - MGIP is user friendly, intuitive and thoroughly documented; 2) flexibility - because 
MGIP is a website, it is compatible with any computer with an internet connection, can be used 
from any geographic location, and there is no installation; 3) speed - MGIP takes just over one 
minute to process a set of 96 trace files; and 4) expandability - MGIP has the potential to 
expand to more loci than those used in MLST and even to other bacterial species. 
INTRODUCTION 
Epidemiological surveillance of N. meningitidis necessitates molecular typing.  Standard 
methods for molecular typing include, but are not limited to, restriction fragment length 




2001), multilocus sequence typing (MLST) (Jolley, 2001; Jolley et al., 2006), and porA, porB, and 
fetA typing (Sacchi et al., 1998; Sacchi et al., 2000; Thompson et al., 2003).  MLST is the most 
modern and widely used of these approaches, and it provides an unambiguous method for 
typing bacterial strains (Maiden et al., 1998).  In MLST, specific regions of seven housekeeping 
genes are sequenced, their alleles are determined, and then the allele calls are concatenated to 
produce a profile called the sequence type (ST), which may then be grouped into a larger 
population called a clonal complex (CC).  MLST analysis used in conjunction with the molecular 
typing methods listed above can provide evidence of possible genetic and epidemiological 
relatedness of strains identified during outbreak investigations and routine surveillance (Enright 
& Spratt, 1999).   
Epidemiological surveillance laboratories world-wide perform MLST using PCR and 
Sanger sequencing.  Standard primers are used to amplify each of the seven loci, and the PCR 
fragments are then characterized using dye-terminator sequencing.  The resulting trace files are 
interpreted by a computer or a human and are converted into unambiguous sequences (base 
calling).  Some computer programs that will make base calls are Phred (Ewing & Green, 1998; 
Ewing et al., 1998) and SeqMan (DNASTAR SeqMan Pro, Madison, WI).  If there is more than one 
sequence read per locus, then those sequences must be assembled to generate a single 
consensus sequence.  Computer programs that can perform assembly include Phrap (Gordon et 
al., 2001) and SeqMan.  The last step in MLST analysis is to determine the allele of the gene by 
comparing the consensus sequence of the trace files to a database of known allele sequences.  
In MLST, even a single nucleotide difference is sufficient to define a new allele and thus the 
comparison between the consensus sequence and the allelic database must be unambiguous.  
The current standard software for MLST analysis, STARS 




programmers, only runs on UNIX/Linux systems, and has performance and usability issues.  
STARS is included in distributions of Bio-Linux, but comprehensive and detailed instructions for 
its set up are necessary (http://pubmlst.org/software/bio-linux/stars/config/).  A commonly 
used alternative to STARS is to make base calls, assemble sequences manually and then use the 
BLAST (Altschul et al., 1997) interface at pubmlst.org (Jolley et al., 2004) to ascertain the identity 
of the MLST alleles.  MLST users and laboratories may use a variety of packages to analyze trace 
files and make base calls, including SeqMan, MEGA (http://www.megasoftware.net), 
BioNumerics (Platt et al., 2006) (http://www.applied-maths.com/bionumerics/bionumerics.htm) 
and the CLC MLST module (http://www.clcbio.com/index.php?id=1018).  These alternatives, 
while viable, either require programming expertise to provide expanded capabilities, 
accessibility to a Linux system, or are prohibitively expensive.  In addition, most of these 
alternatives represent piecemeal and tedious approaches that require a substantial dedication 
of time and resources.  For all of these reasons, MLST analysis can be burdensome for 
laboratories in developing countries and/or in laboratories with fewer resources for personnel 
and computational support.  To address these problems, we have developed an integrated suite 
of MLST analysis tools available at the Meningococcus Genome Informatics Platform (MGIP).  
MGIP presents several key advantages over currently existing analytical methods: 1) 
Ease of use - MGIP runs as a web server, is designed to be user friendly, intuitive, and is 
thoroughly documented.  The documentation is on the website itself and covers any topic the 
user might need to see.  If in any case the documentation is not sufficient, there is a conspicuous 
link to contact the lab for help; 2) Flexibility - MGIP is compatible with any client computer or 
operating system and has been tested using Microsoft Internet Explorer, Mozilla Firefox, Safari, 
and Google Chrome.  Much of this flexibility is given by the cross-browser compatible JavaScript 




minute per set of 96 sequence trace files, more than 5 times faster than STARS.  The speed of 
MGIP can be attributed to the fast constituent programs Phred, Phrap, and BLAST as well as the 
server which is an eight-core machine.  In addition, MGIP’s ability to process multiple loci 
concurrently is a considerable advantage in comparison to other MLST analysis tools, which can 
only process one locus at a time; 4) Expandability – Currently MGIP can analyze sequences from 
over 15 loci, which substantially increases the resolution of sequence typing.  MGIP has the 
potential to include unlimited loci and has the capacity to include other organisms.  We refer to 
MLST analysis with additional alleles as MLST+.  Additional loci can be added in one of two ways: 
either by the administrator of MGIP or by an individual user.  If a locus is added by the 
administrator, then all users can use the new locus database as both a BLAST database and for 
analyzing new trace files.  If a user adds a database, it will be only visible to that user.    
MLST+ ANALYSIS WORKFLOW  
The workflow and programs underlying MLST+ analysis with MGIP are shown in Figure 
2.1.  Users of MGIP first sequence a set of loci to be used in MLST+.  The loci that MGIP can 
process by default are shown in Table A.1.  Current protocols for N. meningitidis surveillance 
laboratories usually yield sequence data from 96-well plates, but the number of wells or traces 





Figure 2.1. MLST+ workflow on MGIP.
makes base calls on each trace to produce a sequence FASTA file and a quality file.  Next, Phrap aligns 
consensus sequence FASTA file and other associated files.  BLAST is then used to match the consensus sequence 
against a database of known MLST+ alleles.  Allelic FASTA files are extracted from the database using fastacmd and 
individually aligned to the consensus sequences to determine coordinates, mismatches, and indels using pairwise 
BLAST.  Alignments between consensus sequences, called allelic sequences, and underlying trace files are displayed 
using the trace file viewer.  The trace file 





  Users upload trace files to the MGIP server for analysis.  First, Phred 








MGIP takes two files as input.  The first file is a zip file of every trace received from the 
sequencing machine in one session.  The second file is a mapping spreadsheet that assigns the 
following properties to each trace file: strain name, sequence typing method, locus, and primer. 
After these two files are submitted to MGIP, the trace files undergo processing:  1) 
Phred makes base calls on each trace file; 2) Phrap assembles groups of trace files to make a 
consensus sequence for each strain/locus; and 3) MGIP uses BLAST against a database of known 
MLST+ alleles to determine the allelic identity of the consensus sequence.  BLAST results that do 
not have perfect matches in the database are flagged (perfect matches have 100% identity, 
100% subject coverage, and no indels).  These flags are shown when viewing results and call 
attention to possibly novel or inaccurate results.  MGIP also includes a trace viewer that shows 
alignments of consensus sequences, allele calls and underlying trace files.  The trace viewer can 
be used to manually edit consensus sequences based on the aligned traces.  The results of MGIP 
analyses are public unless users are registered and logged in at the time analysis is performed. 
MGIP EASE-OF-USE AND UNIVERSAL COMPATIBILITY 
One of the goals for the development of MGIP was to make a system that is simple and 
convenient to use.  This goal is achieved via 1) an intuitive user interface, 2) operating system 
and browser cross-compatibility, and 3) thorough documentation.  These features are 
particularly relevant in the developing world where technical help and systems support may be 
scarce, but they are also applicable to scientists everywhere who do not wish to devote 
substantial resources, in both time and hardware, to computation. 
As opposed to STARS, which requires machines running Linux, MGIP can be used with 
any operating system since it is run on a server with a web browser based client interface.  MGIP 
is compatible with most standards-compliant web browsers because it largely conforms to the 




Scriptaculous frameworks, which are thoroughly tested on many browsers for compatibility, 
were used in the development of MGIP to ensure JavaScript compatibility.  MGIP has been 
tested on Microsoft Internet Explorer, Mozilla Firefox, Safari, and Google Chrome, which 
together account for almost 99% of all web browsers in use (http://marketshare.hitslink.com/, 
last accessed November 1, 2008). 
USING MGIP 
USER ACCOUNTS 
MGIP was developed to allow users to upload private or sensitive data.  Therefore, 
MGIP has a user management system, with few administrators and many users.  Each user 
inherently has all of his or her data and user information privatized so that no other user can 
access them.  To this end, MGIP employs standard web server security measures including MD5 
password encryption and the use of a firewall (http://www.faqs.org/rfcs/rfc1321).  For data that 
is not sensitive, or for scientists who do not wish to use individual accounts, there is a default 
public user setting with full functionality except data privatization.   
UPLOADING TRACES AND RUNNING ANALYSES 
Users upload trace files to MGIP for typing analysis.  The user must create a zip file from 
all sequence trace files and a mapping spreadsheet file which identifies each trace’s strain, 
sequence typing method, locus, and primer.  This spreadsheet is crucial for assembling the 
correct sequences together and provides names to each of the final results.  An automatic 
spreadsheet generator is available which will generate the spreadsheet. 
VIEWING RESULTS BY SET 
Fully automated analysis by MLST+ produces results for sets of traces which are viewed 
on the main page (Figure 2.2).  For each set, the allele calls for each locus are displayed.  For 




sequence and quality scores as given by Phrap; 3) download all files involved in the MLST+ 
analysis workflow; and 4) view trace files and edit the consensus sequence, thus allowing the 
user to manually adjust the results.  BLAST results are reported in default format and for each 
hit show the allele names, bit scores and e-values along with pairwise query-hit sequence 
alignments.  Consensus sequences are shown in FASTA format, with each nucleotide shown in a 
color corresponding to a range of quality scores.  Loci that yield ambiguous results from the 





Figure 2.2. Viewing MGIP+ results.  
and their allele calls are shown.  (B) Options are shown for each strain/locus that allow the user to view more details.  
(C) When an allele call is not a perfect match, a flag appears.  (D) On mouseover (when the mouse pointer hovers over 
the flag), a message giving information as to why it is not a perfect match appears.
 
 
To view trace files, we have developed a trace viewer Java applet that displays the 
alignment of all traces involved in the assembly process, the consensus sequence, and the allelic 
sequence (Figure 2.3).  The applet automatically marks all discrepancies between the trace file 
base calls, the consensus sequence, and the most similar allele, to facilitate scanning for 
inconsistencies.  Trace amplitudes can be adjusted individually, and although the tr
trimmed to show only the aligned regions, there is an option to view trimmed edges.  The 
consensus sequence can be edited by changing, adding, or deleting bases using the trace viewer.  
Once manual editing is completed, the workflow analysis start
that the main page results are updated.  
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(A) The user can select a set of results to view.  For each set, all strain/loci 
 








Figure 2.3. The trace viewer and editor applet.
allelic sequence and the traces.  The applet tools allow users to
consensus sequence, 3) insert/delete consensus sequence nucleotides, 4) undo/redo any action, and 5) save a 




VIEWING RESULTS IN T
The results of MLST analyses are also displayed in the strain table, which shows the 
allelic profile, ST and CC for each strain that has been analyzed (Figure 
55 
  The consensus sequence acts as a backbone when aligning the 
 1) alter the amplitude of the traces, 2) edit the 
HE STRAIN TABLE 
A.
 
n be copied and 




user account, the strain table is automatically and continually populated with the combined 
results of all sets that have been analyzed.  If fewer than seven known alleles have been 
unambiguously characterized for any given strain, a list of all possible STs and CCs is shown. 
REFERENCE PAGES 
To aid in data analysis, all reference data in the MGIP database has been made 
transparent and available on the reference pages.  The ST reference page allows the user to type 
in an ST number and to retrieve the alleles associated with that ST.  Alternatively, a CC number 
can be input to retrieve all STs associated with it.  The locus reference page shows every locus 
that can be analyzed using MGIP.  For each locus, the sequence typing method and the length of 
the allele are shown; all sequences in the locus databases can be downloaded.  The locus 
reference page also has a BLAST interface, which accepts one or multiple FASTA query entries 
for comparison against the locus database.   
PERFORMANCE VALIDATION 
MGIP was compared against two other methodologies to validate performance in terms 







where Sn is sensitivity, TP is the number of true positives, and FN is the number false negatives.  
In this study, a true positive is defined as an unambiguously identical match from the trace file(s) 
to the allelic database, and a false negative is defined as no match when there should be one.  
Specificity cannot be measured because all methodologies in this study filter out false positives 
before they are reported.  Speed is calculated simply as the time elapsed from upload to the end 

















MGIP 660 18 97.4% 63±0.58 
STARS 653 35 94.9% 323±30 









 speed (seconds) 
MGIP 323 6 98.2% 75±2 
SeqMan  319 8 97.6% 1520±173 
a
 For the MGIP vs. STARS comparison, 17 sets of MLST data were tested which were composed of trace files over 
691 strain/loci.  The speed test was performed on 3 randomly selected sets, composed of 126 strain/loci.   
b
 For the MGIP vs. SeqMan method comparison, 10 sets of fetA were tested in the SeqMan comparison, totaling 
331 loci.  The speed test was performed on 3 randomly selected sets, composed of 103 strain/loci. 
c
 TP is true positives. 
d
 FN is false negatives. 
e
 Sn is sensitivity. 
f
 Speed is shown as an average per trace file set (84 traces in the STARS comparison, 96 traces in the SeqMan 
comparison), plus or minus standard deviation.  The speed tests were performed over a 1 Gigabyte per second 
network connection and therefore the upload time was negligible.  However, the upload time from a slower 
connection will understandably increase the time to process a set of trace files.  Approximate times for uploading a 





The first methodology compared to MGIP was STARS, which is the current standard for 
MLST analysis.  For comparison to STARS, 17 MLST sets were analyzed totaling 691 strain/locus 
combinations.  MGIP showed 97.4% sensitivity compared to 94.9% sensitivity for STARS (Table 
2.1).  In addition to being more sensitive, MGIP is also substantially faster than STARS.  On 
average, MGIP finished analyzing a set of 84 trace files in 63 seconds compared to 323 seconds 
for STARS (Table 2.1).  
The second methodology compared to MGIP was the “SeqMan method,” where a 
consensus sequence is created from trace files using SeqMan and used as a query in the Pubmlst 
BLAST interface.  SeqMan is used when non-standard MLST alleles are being analyzed, and 
requires substantial manual intervention by the user.  Ten sets totaling 331 fetA traces were 
analyzed for the comparison of MGIP to the SeqMan method.  MGIP showed 98.2% sensitivity 
compared to 97.6% for the SeqMan method (Table 2.1).  MGIP showed an even greater relative 
increase in speed over SeqMan.  MGIP completed the ten fetA trace sets in 75 seconds 
compared to 1520 seconds for the SeqMan method (Table 2.1). 
FURTHER DEVELOPMENT OF MGIP 
There are several lines of further development of MGIP planned.  MGIP allows for the 
discovery of novel alleles and/or STs, which cannot be named or curated until they are sent to 
one of the central repositories of MLST data such as Pubmlst.  We have been collaborating with 
the developers of Pubmlst to design an application programming interface that will allow MGIP 
users to directly submit new alleles and new STs.  In addition to N. meningitidis, there are many 
more bacterial pathogens that are analyzed using MLST and MGIP will add the capacity to 
analyze additional organisms in the near future.  The MGIP website is being translated to other 





The web based design and implementation of MGIP helps to ensure that it stands alone 
among MLST analysis methods in terms of cost, speed of processing, ease-of-use, cross-
compatibility and expandability.  These features are particularly relevant to laboratories in the 
developing world, many of which may lack access to the level of computational infrastructure 
and support currently needed for MLST analysis.  The use of simple web-based analytical 
platform should allow any investigator with Internet access to rapidly analyze his or her MLST 
data.  Furthermore, MGIP is designed to be scalable to accommodate MLST+ analysis of multiple 
non-standard alleles.  This feature should enable the expansion of current MLST based 
surveillance approaches.   
The development of MGIP has been done in close contact with typing centers around 
the world to ensure that it will emerge as the global standard for MLST+ analysis.  Labs that have 
been testing MGIP include the Meningitis laboratory of CDC in the USA, the Health Protection 
Agency in England, Martin Maiden’s research group at the University of Oxford, and the 
National Institute for Communicable Diseases in South Africa.  MGIP has been tested on over 
1000 different strain/locus combinations, and the results show that it is 1-3% more sensitive and 
an order of magnitude faster than existing methods for MLST+ analysis.   
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THE INFLUENZA GENOMICS PLATFORM: A SYSTEM FOR 
ANALYZING SMALL TARGET REASSORTANT SCREEN DATA 
ABSTRACT 
The Influenza Genomics Platform (InGen) is a suite of computational tools for the analysis of 
Small Target Reassortant Screen (STaRS), at http://flu.biology.gatech.edu.  STaRS is used to 
generate clade profiles to characterize strains of influenza, which has the potential to cause 
massive outbreaks.  Furthermore InGen can utilize STaRS to display reassortment quickly and 
easily to the laboratorian. 
INTRODUCTION 
INFLUENZA 
Influenza is a virus that belongs to the Orthomyxoviridae family.  The genome is divided into 
eight linear segments of negative-sense single-stranded RNA and codes for ten genes.  The 
epidemiologically relevant proteins that these ten genes code for are hemagglutinin (HA) and 
neuraminidase (NA).  HA is the protein that recognizes and targets host cells, and it has a fusion 
domain to give access to the host cell.  NA is the protein that allows the virus to be released 
from the host cell. 
Influenza causes the flu whose symptoms include chills, fever, sore throat, muscle pains, 
severe headache, coughing, and fatigue.  It is an airborne virus, usually spread by coughing or 
sneezing.  Influenza spreads in seasonal epidemics and results in hundreds of thousands of 




pandemics including the 1918 Spanish Flu, the H5N1 Avian Flu which is still ongoing, and the 
2009 H1N1 pandemic. 
To survey the spread of influenza worldwide, scientists have created typing methods.  
Influenza can be divided into genera, the major ones being A, B, and C.  Influenza A is the most 
common source of human flu and can be further divided into serotypes (or subtypes).  These 
types are based on the variant of HA and NA and some examples are H1N1, H1N2, and H5N1.  
However, even these subtypes are very diverse and so they are further subdivided into clades.  
For example, the strains related to the 2009 pandemic strain is one clade of the H1N1 serotype. 
At times if a host is infected with two different strains, influenza can exchange segments of 
its 8-segment genome with other virions’ segments.  This process is called reassortment, and the 
new strain can be described as a reassortant strain.  Therefore a person coinfected with H1N1 
and H2N2 can produce the reassortant subtypes H1N2 and H2N1.  This is one example of how 
influenza can evade the immune system. 
CURRENT METHODS OF SURVEILLANCE 
The CDC Influenza Division has been charged with observing and answering flu epidemics.  
Its current methods involve looking at the subtype and even the clade of the virus.  The current 
system that CDC uses is called Ibis, which makes use of the Ibis T5000 universal biosensor 
platform (Sampath et al., 2007).  The Ibis methodology involves creating cDNA through reverse 
transcription and amplifying a small segment of the influenza genome.  Next, the small target is 
sent though a mass spectrometer.  Generically, this methodology is called RT-PCR/ESI-MS.   The 
raw result of RT-PCR/ESI-MS is a mass spectral data plot.  This plot can be analyzed and matched 
with one of several reference plots to determine the clade of the virus. 
RT-PCR/ESI-MS is beneficial because it is somewhat quick and does not require much human 
intervention.  Additionally it allows for quick detection of reassortant which would help advise 
 
 
on which clades to vaccinate against in a flu season.  However, RT
not beneficial because it is a method of changing digital nucleotide information into analog mass 
spectral data.  Furthermore, it is difficult for laboratories around the world to standardize the 
results from this methodology.  Remaining on the digital level and aligning nucleic acid 
information would be more beneficial because 1) it is unambiguous, 2) it
laboratories, and 3) it is easily standardized between laboratories.
Therefore, the CDC Influenza Division’s Sequencing Activity is moving away from Ibis and will 
be using a nucleic acid approach called Small Target Reassortant Screen 
in the genome covering all eight segments
3.1).  Sanger sequencing is performed on these small targets which are typically less than 100 nt.  
The sequence is inferred from the raw 
against a database of target variants.  The closest variant, as defined by a low BLAST e
determines the clade that the query sequence belongs to.  Additionally, if two sequences from 
the same genome match two different clades, then a reassortant event will be detected.
 
Figure 3.1.  The influenza genome.
the genes for which they encode.  Segments 4 and 6 encode for the HA 




(STaRS).  Small targets 
, as defined by PCR primer pairs, are chosen
data obtained from Sanger sequencing and is compared 
  The influenza genome is comprised of eight segments which are listed after 
and NA genes which determine the subtype 
-MS is on the whole, 









Even with these well-defined techniques, information still escapes CDC because it is not 
reported to CDC.  There are many health laboratories around the U.S. and the world, each with 
their own records of influenza.  However their results are not reported to CDC very often, which 
results in a national or global delay in influenza surveillance.  As a result, it is difficult to predict 
which clades or even which subtypes might be circulating in a given time period.  A consequence 
of this information lag is that vaccine preparation can go awry or can be delayed.  Therefore 
some national or global data-sharing plan is necessary to combat influenza. 
Fortunately our laboratory has created the Influenza Genomics Platform (InGen) which is 
the bioinformatic accompaniment to STaRS.  InGen uses a digital approach to STaRS in that it 1) 
reads trace files, 2) assembles a consensus sequence at each target, and 3) performs BLAST to 
infer variant and profile calls.  In this article, we will discuss how InGen has been developed to 
be a highly suitable auxiliary to worldwide usage of STaRS.  InGen is available at 
http://flu.biology.gatech.edu. 
INGEN FACILITATES STARS ANALYSIS 
A COMPUTATIONAL APPROACH 
STaRS analysis can be thought of as a workflow.  A sequence from a genome must be read 
and combined with overlapping targets.  The closest sequence from a reference database to 
each target identifies its clade/subtype/serotype.  If sequences in a genome differ in origin, then 
the virus can be considered reassortant.  For example, if targets from segments 1-7 come from 
one clade and segment 8 comes from another clade, then the virus is reassortant.  
Reassortment causes a heterogeneous genome, while other genomes are homogeneous. 
InGen facilitates this workflow computationally (Figures 3.2 and 3.3).  Raw Sanger sequence 
data that overlaps a target site for a particular strain is sent to InGen in a group.  Each trace file 




presence of their quality files, are assembled to produce a comprehensive target’s sequence and 
quality file.  This consensus sequence represents an overall region that is covered by the target 
sequences.  Last using BLAST, these consensus sequences are compared against a curated 
reference database that represents each clade.  There is one database per target.  The target 
sequence is assigned a clade according to the top hit in the target database.  The result is a clade 
call. 
Each target’s clade call is combined into a profile which is compared against a curated STaRS 
profile database.  STaRS profiles are named using free text (e.g. H1N1pdm for the 2009 H1N1 
pandemic strain).  If the clade calls are from more than one STaRS profile then it is reassortant.  
However, if the clade calls are from the same profile, then no reassortment has taken place. 
DATA SHARING 
Much of STaRS data is sensitive, and so InGen has a user system (Table 3.1).  Users may 
register and log in before analyzing data.  Therefore, all user data is initially only available to the 
user who analyzed it.  However, InGen also allows for groups.  Sets of data, which are all data 
that are analyzed at one time and usually from a 96-well plate, can be added to a group. 
A user can create a group by going to the manage groups menu.  A link is there to create a 
group, and then a name and description must be filled in.  After the group is created, the user 
becomes the group administrator.  Users can be added to a group and can be given permissions: 
read, edit, add others, etc.  Group administrators have carte blanche permissions.  Also after the 
group is created, sets can be added.  Sets that are associated with a group are visible to all 
members, as long as they have read permissions. 
InGen has an application programming interface (API) which is a form of web services.  An 
API is a method of accessing a web tool, or suite of tools such as those on InGen, and sending 




from the command line.  These API commands are thoroughly documented on the site using 
PHPDoc, which is similar to the standardized and well-known JavaDoc. 
The disadvantage of using an API is that a user cannot experience the graphical interface 
that the website provides.  However, the advantages are great to a user with programming 
experience.  The core functionality of InGen is exposed when using the API, meaning that every 
function of the platform runs more quickly.  The styling of the site and the JavaScript 
functionality is not loaded, which cuts down on load time significantly.  Another major 
advantage is that a programmer could incorporate InGen functionality into a script. 
An example of such a script would be one that finds clade calls for all trace files in a given 
directory and reports any reassortment.  In this scenario, a laboratorian would run a sequencing 
machine and allow the results to be deposited into a folder upon completion.  Early in the 
morning, this script would generate profiles for every strain and highlight those strains that are 





Figure 3.2.  The InGen workflow.
Green, 1998; Ewing et al., 1998)
Next, Phrap (Gordon et al., 2001)
BLAST (Altschul et al., 1997) is then used to match the consensus sequence against a target database with 
representative sequences for each clade.  Allelic FASTA files are extracted from the database using fastacmd and 
individually aligned to the consens
BLAST.  Alignments between consensus sequences, called target sequences, and underlying trace files are displayed 
using the trace file viewer.  The trace file viewer can be used t
aligned trace files.     
 
 
Figure 3.3.  The InGen front page.
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  Users upload trace files to the InGen server for analysis.
 makes base calls on each trace to produce a sequence FASTA file and a quality file.  
 aligns and produces a consensus sequence FASTA file and other associated files.  
us sequences to determine coordinates, mismatches, and indels using pairwise 
o manually edit consensus sequences based on the 
  From here, the user can access any InGen functionality.
 







InGen is a suite of tools that answers several issues in the influenza surveillance world.  One 
problem is detection of reassortment.  InGen can automatically detect all reassortment, given 
trace files of several targets in the influenza genome.  Another problem is economical.  InGen is 
free software that promises to be cutting edge and useful to any influenza typing laboratory.  It 
is also reliable.  Once data is sent to the InGen server, it is stored and analyzed independent of 
the laboratorian’s desktop computer.  These results can be downloaded at any time to view 
them.   
InGen rests on a powerful computer.  The server is a 2 quad core Intex Xeon 1.60 GHz with 
8GB of RAM and four 500GB hard drives.  The operating system is Ubuntu 8, and the server uses 
PHP 5.2, Mysql 5.0, and Apache 2.  These specifications are crucial for its speedy analysis and 
data sharing duties. 
Because InGen is cutting edge and because the CDC Influenza Division recommends its 
usage, many other laboratories worldwide will be using InGen.  In addition there are basic users 
who can choose to share data through groups, but then there are managers of influenza (Table 
3.1).  These managers will be picked by the CDC Influenza Division, and usage of InGen gives 
rights to these particular users for surveillance of influenza.  With the combination of managers 
and worldwide usage, InGen will have the capability to remove any significant lag time between 








Table 3.1.  InGen user classes. 
 Access level Magnitude of estimated 
users 
Administrator Have total control over InGen and are likely to be the 
developers of the project.  Administrators can delete users, 
view information about users, and log in as another user. 
ones 
Manager May view all data as it pertains to one organism (especially 
influenza), without regard to which group the data belong to. 
tens 
Group Administrator Each group administrator is in control of a particular group.  
May add or remove users from a group.  May alter 
permissions of group members as it relates to the group 
(view, edit, etc.). 
hundreds 
User May view and edit their set data.  May view and edit group 
data, as allowed by each group administrator.  May create 








CG-PIPELINE, A COMPUTATIONAL GENOMICS PIPELINE 
FOR PROKARYOTIC SEQUENCING PROJECTS 
ABSTRACT 
Motivation: New sequencing technologies have accelerated research on prokaryotic 
genomes and have made genome sequencing operations outside major genome sequencing 
centers routine. However, no off-the-shelf solution exists for the combined assembly, gene 
prediction, genome annotation, and data presentation necessary to interpret sequencing data. 
The resulting requirement to invest significant resources into custom informatics support for 
genome sequencing projects remains a major impediment to the accessibility of high-
throughput sequence data. 
Results: We present CG-Pipeline, a self-contained, automated, high-throughput, open 
source genome sequencing and computational genomics pipeline suitable for prokaryotic 
sequencing projects.  The pipeline has been used at the Georgia Institute of Technology and the 
Centers for Disease Control and Prevention for the analysis of Neisseria meningitidis and 
Bordetella bronchiseptica genomes.  The pipeline is capable of enhanced or manually assisted 
reference-based assembly using multiple assemblers and modes; gene predictor combining; and 
functional annotation of genes and gene products. Because every component of the pipeline is 
executed on a local machine with no need to access resources over the Internet, the pipeline is 
suitable for projects of a sensitive nature. Annotation of virulence-related features makes the 




Availability and Implementation: The pipeline is licensed under the open-source GNU 
General Public License and available at the Georgia Tech Neisseria Base 
(http://nbase.biology.gatech.edu/). The pipeline is implemented with a combination of Perl, 
Bourne Shell, and MySQL and is compatible with Linux and other Unix systems. 
INTRODUCTION 
Genome sequencing projects, pioneered in the 1990s (Fleischmann et al., 1995), require 
large-scale computational support in order to make their data accessible for use and 
interpretation by biologists. Large sequencing centers have traditionally employed or 
collaborated with teams of software engineers and computational biologists to develop the 
software and algorithms for sequencing hardware interfaces, enterprise data storage, sequence 
assembly and finishing, genome feature prediction and annotation, database mining, 
comparative analysis, and database user interface development. While many of the components 
developed by these teams are now available online under open-access terms, the development 
of new, high-throughput sequencing technologies has necessitated updates to these tools and 
development of even more sophisticated algorithms to address the challenges raised by the new 
data. These new technologies – 454 pyrosequencing (Margulies et al., 2005), ABI SOLiD 
(Shendure et al., 2005), and Illumina (Bentley et al., 2008) – are now collectively referred to as 
second generation sequencing technologies. Similar updates will be needed as the third 
generation of sequencing technologies, such as Pacific Biosciences’ SMRT sequencing (Eid et al., 
2009), enter production use. New and improved tools released for these technologies on a 
monthly basis include assemblers, mapping algorithms, base calling and error correction tools, 
and a multitude of other programs. Because of this fast pace of development, few experts are 




rate limiting step in genome sequencing projects is no longer the experimental characterization 
of the data but rather the availability of experts and resources for computational analysis. 
At the same time, the increased affordability of these new sequencing machines has 
spawned a new generation of users who were previously unable to perform their own genome 
sequencing, and thus collaborated with large sequencing centers for genome sequencing and 
subsequent computational analysis.  While these users are now able to characterize genomes 
experimentally in house, they often find themselves struggling to take full advantage of the 
resulting data and to make it useful to the scientific community since the informatics support for 
their genome projects is not sufficient. 
Several large sequencing consortia (Aziz et al., 2008; Markowitz et al., 2009; Seshadri et al., 
2007) have produced comprehensive, centralized web-based portals for the analysis of genomic 
and metagenomic data. While extremely useful for many types of projects and collaborations, 
these solutions inherently result in a loss of data processing flexibility compared to locally 
installed resources and may be unsuitable for projects dealing with sensitive data. Recently, 
another group (Stewart et al., 2009) has published DIYA, a software package for gene prediction 
and annotation in bacterial genomes with a modularized, open source microbial genome 
processing pipeline. However, DIYA does not include a genome assembly component, and does 
not provide for the combination of complementary algorithms for genome analysis. 
To address the outstanding challenges for local computational genomics support, we have 
developed a state of the art, self-contained, automated high-throughput open source software 
pipeline for computational genomics in support of prokaryotic sequencing projects, which we 
call CG-Pipeline, for “Computational Genomics Pipeline.”  To ensure the relevance of our 
pipeline, we checked the latest developments in computational genomics software for all stages 




comparative surveys, and selected what we deemed to be the most suitable software packages. 
The pipeline is self-contained; that is, we used locally installable versions of all third-party tools 
instead of web-based services provided by many groups. We chose to do so for three reasons: 
first, because some of the applications we envision for this pipeline are of sensitive nature; 
second, to enhance robustness to external changes (e.g., online API changes or website address 
changes); and third, to improve the ability of developers to customize and derive from our 
pipeline. The pipeline is also automated and high-throughput: all components are organized in a 
hierarchical set of readily modifiable scripts, and the use of safe programming practices ensures 
that multiple copies of the pipeline can be run in parallel, taking advantage of multiple 
processors where possible. 
Importantly, by using and combining the outputs of competitive, complementary algorithms 
for multiple stages of genome analysis, our pipeline allows for substantial improvement upon 
single-program solutions. The use of multiple algorithms also provides a way to improve 
robustness and conduct more comprehensive quality control when the output of one program is 
significantly different from that of another.  
Computational support provided to prokaryotic genome projects by our pipeline can be 
subdivided into three stages: first, sequencing and assembly; second, feature prediction; and 
third, functional annotation. For the assembly stage, we developed a custom protocol specific to 
454 pyrosequenced data, which resulted in a significant improvement to assembly quality of our 
test data compared to the baseline assembler bundled by the manufacturer. Other assemblers 
can be plugged in if necessary, and data from other sequencing technologies such as ABI SOLiD, 
Illumina and Sanger capillary-based machines can be used. For the prediction stage, we again 
included a custom combination of feature prediction methods for protein-coding genes, RNA 




The annotation stage includes several types of protein functional prediction algorithms. We also 
developed components for comparative analysis, interpretation and presentation (a web-based 
genome browser), which can be used downstream of our pipeline. 
We have tested the pipeline on the bacterium Neisseria meningitidis, which is a human 
commensal of the nasopharynx and which can sometimes cause meningitis or septicemia 
(Rosenstein et al., 2001). When N. meningitidis does cause disease, it can be devastating with an 
approximately 10% fatality rate and 15% sequelae rate. N. meningitidis is a highly competent 
organism with a high recombination rate, and large chromosomal changes are common (Jolley 
et al., 2005; Schoen et al., 2008). This complicates computational genome analysis and makes N. 
meningitidis an appropriately challenging test for our pipeline. To demonstrate the general 
applicability of the pipeline, we have also tested it on a different pathogen, Bordetella 
bronchiseptica. B. bronchiseptica is a Gram-negative bacterium that can cause bronchitis in 
humans, although it is more commonly found in smaller mammals (Parkhill et al., 2003). Much 
like Neisseria, Bordetella has extensive plasticity, likely due to the large number of repeat 
elements (Gerlach et al., 2001). Here, we analyze the first two complete genome sequences of 
B. bronchiseptica strains isolated from human hosts. 
The rest of this paper is organized as follows. The System and Methods section describes the 
genomes which we used to test CG-Pipeline, overall organization of the pipeline, and details of 
the algorithms used to perform tasks in the pipeline. In the Discussion section, we discuss the 
objectives of our work on the pipeline and how these relate to larger developments in 





SYSTEM AND METHODS 
GENOME TEST DATA 
N. meningitidis genomes were characterized via 454 pyrosequencing (Margulies et al., 2005) 
using either a half or one quarter plate runs on the Roche 454 GS-20 or GS Titanium instrument 
(Table 4.1). For each genome, a random shotgun library was produced using Roche protocols for 
nebulization, end-polishing, adaptor ligation, nick repair and single-stranded library formation. 
Following emulsion PCR, DNA bound beads were isolated and sequenced using long read (LR) 
sequencing kits. The number of reads produced in the experiments ranged from 200,000 to 
600,000, and the average read lengths were between 100 and 330 bases. These data yielded 
47.6-94.3 million bases per genome amounting to 20-40x coverage for the approx. 2.1 
megabase N. meningitidis genomes. After read trimming and re-filtering to recover short quality 
reads, the data were passed to the first stage of the pipeline – genome assembly.  
CG-PIPELINE DEVELOPMENT 
The CG-Pipeline has been developed in two phases.  The first fully functional version of CG-
Pipeline (v0.2) was released in June 2010 (Kislyuk et al., 2010).  The second phase of 
development (CG-Pipeline v0.3) entailed a number of enhancements in response to user 
requests and new data sources.  Below, we describe the distinct functionality and features made 


































2.2M Z2491 197067 47569493 241 21× GS-20 
M10699 32/B Oregon, 
USA 
2003 
2.2M MC58 418751 81775264 195 37× GS-20 
















2.2M Z2491 283888 84013571 296 38× GS Ti 
M5178 32/B Oregon, 
USA 
1998 
2.2M MC58 270332 88664981 328 40× GS Ti 
M15293 32/B Georgia, 
USA 
2006 











5.3M RB50 533099 228467710 429 43× GS Ti 
 
a 
Sequence type (ST) denotes the allelic profile assigned by multilocus sequence typing (MLST) (Holmes et al., 
1999; Maiden et al., 1998) on the basis of seven loci within well-conserved house-keeping genes.  N. meningitidis 
isolates are divided into serogroups (SG) by immunochemistry of polysaccharides present in their antiphagocytic 
capsule. 
b
 The geographic region in which each strain was originally collected and the date that the isolate was collected. 
c
 Strain ID of the closest complete genome available in GenBank, as determined by 16S RNA phylogeny as well as 
whole-genome sequence identity, which agreed in all cases. 
d
 Coverage denotes the average number of sequencing reads overlapping at a given position in the genome, 
calculated as the total number of bases sequenced divided by the estimated length of the genome.  
e
 The standard of the 454 pyrosequencing instrument and reagents used to sequence the data. 
f




PIPELINE ORGANIZATION V0.2 
The analytical pipeline consists of three integrated stages: genome assembly, feature 
prediction and functional annotation. Each stage consists of a top-level execution script 
managing the input, output, format conversion, and combination of results for a number of 
distinct software components. A hierarchy of scripts and external programs then performs the 
tasks required to complete each stage of analysis (Figure 4.1) 
PIPELINE ORGANIZATION V0.3 
The overall architecture of CG-Pipeline has been retained for version 0.3 and additional 
features have been added to each of the three stages (Figure 4.2).  The assembly stage now 
includes an additional assembly software component, the Velvet assembler, along with an 
automated tool for comparing multiple assemblies and selecting the best assembly based on 
standard annotation metrics.  The feature prediction stage has been enhanced by the addition 
of the RNAmmer software component that predicts ribosomal RNA loci.  The functional 
annotation stage has been modified to produce three standard output files containing the 
sequences and locations of all annotated features.  These three distinct file formats – GenBank, 
GFF, FASTA – are all standard and portable among multiple bioinformatics applications.  Finally, 
the new version includes a single wrapper script around all three stages that allows for fully 
integrated automation of the entire pipeline.  This enhancement moves the pipeline closer to its 




Figure 4.1.  Chart of data flow, major components and subsystems in the CG
presented: genome assembly, feature prediction and functional annotation. Each subsystem consists of a top
execution script managing the input, output, format conversion, and combination of results for a number of 
components. A hierarchy of scripts and external programs then performs the tasks required to complete each stage. 
The legend for the flowchart indicates the identities of the distinct pipeline components: data, pipeline component, 




Figure 4.2.  Chart of data flow, major components and subsystems in 
subsystem components: genome assembly, feature prediction and functional annotation.
indicate input/output files, orange boxes show individual program components, and blue boxes indicate custom 
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Genome assembly was performed by evaluating multiple configurations of assemblers 
including the standard 454 assembler, Newbler (version 2.3), as well as the Celera Assembler 
(Miller et al., 2008), the Phrap assembler (http://www.phrap.org/) and the AMOScmp mapped 
assembler (Pop et al., 2004). Several other assemblers were evaluated but ultimately excluded 
from the pipeline due to use limitations: for instance, the ALLPATHS 2 assembler (MacCallum et 
al., 2009) required paired-end reads to operate; our evaluation data contained no paired-end 
reads, and such a requirement unnecessarily constrains the user’s options. The widely used 
Velvet assembler (Zerbino & Birney, 2008) was originally developed as a de novo assembler for 
Illumina sequencing technology, but its capability has been extended to accommodate 454 data 
as well. However, we were unable to configure the Velvet assembler to produce a usable 
assembly or take advantage of reference genomes using 454 data alone. 
Comparative evaluation of our initial assembly results indicated that reference assemblies of 
N. meningitidis genomes using previously finished strains were of superior quality to de novo 
assemblies.  Using the most appropriate reference strains, it was found that Newbler and 
AMOScmp complement each other’s performance in the reference assembly stage, with 
Newbler being able to join some contigs AMOScmp left gapped and vice versa.  As a result, we 
decided to use a combination of these two assemblers’ outputs for the final assembly.  Then, 
the Minimus assembler (Sommer et al., 2007) from the AMOS package, a simple assembler for 
short genomes, was used to combine the constituent assemblies.  
We also evaluated alternative base calling algorithms for 454 pyrosequencing data (Quinlan 
et al., 2008) but detected no improvement. Over the course of our project, accuracy of base 
calling in the Newbler assembler was reported to be significantly improved. We used the latest 




An optional component of the pipeline was created for frameshift detection using FSFind 
(Kislyuk et al., 2009). Frameshifts in protein-coding sequences are a known result of 
pyrosequencing errors caused by undercalls and overcalls in homopolymer runs (Kuo & 
Grigoriev, 2009). Briefly, this package creates a GeneMark model of the genome, makes gene 
predictions, and then scans the genome for possible frameshift positions on the basis of ORF 
configuration and coding potential. Once the possible frameshift sites are identified, a putative 
translation of the protein possibly encoded by the broken gene is compared against a protein 
database (SwissProt by default). The predicted frameshift site is also scanned for adjacent 
homopolymers. A heuristic set of confidence score cutoffs is then used to provide a set of 
frameshift predictions while minimizing the false positive rate. The predicted frameshift sites 
can then be verified experimentally or corrected speculatively. The user can inspect the dataset 
to decide whether locations predicted to contain frameshifts break gene models, and patch the 
sequences to fix up these positions.  The prediction stage can then be re-run to correct the gene 
predictions. While further experimental analysis to address such errors is desirable (e.g., 
targeted PCR of predicted error locations or a recently popular choice of combining sequencing 
technologies such as 454 and Illumina), it incurs extra costs which we aim to avoid. 
Unfinished assemblies produced in this stage contained 90-300 contigs each. No paired-end 
libraries or runs were available for the strains analyzed, and therefore scaffolding of the contigs 
was a challenge.  Manual examination of the assemblies using the MAUVE (Darling et al., 2004) 
multiple whole-genome alignment and visualization package revealed numerous locations 
where contigs could be scaffolded with a small gap or minimal overlap (Figure 4.3). As an 
optional step, we produced a table of such positions and a script which would scaffold contigs 
joined by the gap.  Then, a manual gap joining stage used the layout of the contigs according to 




each gap, adjacent contig alignments and reference annotation in the MAUVE visualization tool. 
Although there is a possibility that rearrangements exist in those gaps as mapped to the closest 
reference genome, joining was only done after manual examination on a case-by-case basis in 
positions of high homology and full consensus between four of the reference strains, to 
minimize this possibility.  While we provide the scripts and data format definitions necessary to 
complete this stage of the pipeline, it involves manual processing of the assembly and is 
therefore optional.  This component is similar in function to Mauve Contig Mover (Rissman et 
al., 2009) but expands upon it in several ways. An option is provided in the pipeline to use 








Figure 4.3.  Comparative analysis of draft assembly with MAUVE.  The top pane represents the active assembly; 
vertical lines indicate contig boundaries (gaps). The reference genomes are arranged in subsequent panes in order of 
phylogenetic distance. Blocks of synteny (LCBs) are displayed in different colors (an inversion of a large block is visible 
between panes 1–2 and 3–5). Most gaps within LCBs were joined in the manually assisted assembly, while considering 







The manually assisted genome assembly procedure resulted in an order-of-magnitude 
decrease in the number of gaps in comparison to the Newbler assembler (which in turn 
performed the best out of all standalone assemblers evaluated). In addition, the fully automated 
assembly metrics (N50 and contig count at equal minimal size) are an approximately 20-50% 
improvement upon baseline Newbler performance (Table 4.2). 
 
 
Table 4.2.  Summary of assembler performance (v0.2). Data for each strain are presented in rows. Statistics from 
standalone assemblers (Newbler and AMOScmp) are presented together with results of the combining protocol 
(default output of the pipeline) and an optional, manually assisted predictive gap closure protocol. 
Strain ID Newbler statistics AMOScmp statistics 










M13220 175, 2.07M 22K, 106K 202, 2.06M 21K, 77K 
M10699 102, 2.10M 52K, 143K 116, 2.10M 43K, 113K 
M15141 147, 2.06M 33K, 171K 190, 2.05M 22K, 115K 
M9261 99, 2.09M  51K, 184K 133, 2.07M  37K, 170K 
M18575 133, 2.09M 30K, 172K 147, 2.09M 29K, 88K 
M5178 89, 2.13M 56K, 136K 107, 2.12M 42K, 131K 
M15293 92,2.08M  52K, 144K 110, 2.06M 42K, 132K 
BBE001 146, 5.05M 70K, 212K 178, 5.04M 61K, 173K 
BBF579 272, 4.84M 57K, 88K 321, 4.84M 46K, 94K 
 Automatic combined assembly Manual combined assembly 








M13220 195, 2.25M 31K, 107K 57, 2.30M 1.8%, 398K 
M10699 83, 2.17M 59K, 143K 40, 2.18M 1.1%, 435K 
M15141 139, 2.21M 36K, 171K 50, 2.28M 2.0%, 759K 
M9261 128, 2.16M  64K, 231K 27, 2.21M 1.6%, 866K 
M18575 220, 2.40M  53K, 231K N/A
c
 N/A 
M5178 104, 2.17M 59K, 136K N/A N/A 
M15293 107, 2.10M  59K, 144K N/A N/A 
BBE001 214, 5.03M 80K, 252K N/A N/A 
BBF579 272, 4.84M
 b
 57K, 88K N/A N/A 
a
 N50 is a standard quality metric for genome assemblies that summarizes the length distribution of contigs. It 
represents the size N such that 50% of the genome is contained in contigs of size N or greater. Greater N50 values 
indicate higher quality assemblies. 
b 
No improvement was detected from the combined assembly in strain BBF579, and the original Newbler 





Table 4.3.  Summary of assembler performance (v0.3). Data for each strain are presented together with results of 
the combining protocol (default output of the pipeline).  
Strain ID Automated combined assembly 
 Contigs > 500 nt Total size N50
a
 Longest contig 
M13220 168 2.17M 28K 80K 
M10699 87 2.20M 52K 143K 
M15141 124 2.05M 34K 233K 
M9261 73 2.12M 69K 230K 
M18575 87 2.37M 45K 172K 
M5178 76 2.30M 56K 136K 
M15293 81 2.16M 56K 144K 
BBE001 126 5.09M 80K 212K 
BBF579 224 5.08M 41K 96K 
a
 N50 is a standard quality metric for genome assemblies that summarizes the length distribution of contigs. It 
represents the size N such that 50% of the genome is contained in contigs of size N or greater. Greater N50 values 




The contigs in the assembly stage output were named according to the following format: 
prefix_contig#, where the prefix represents a unique strain identifier and # represents the 
zero-padded sequential number indicating the contig’s predicted order on the chromosome. For 
example, the 25th contig for the N. meningitidis strain M13220 assembly would be named as 
CDC_NME_M13320_025. The prefix used in the pipeline is configurable by the user with a 
command line option. 
ASSEMBLY V0.3 
I have incorporated the Velvet assembler at the assembly stage (Figure 4.2).  As noted in the 
original CG-Pipeline publication Velvet does not add much to the final output of CG-Pipeline 
(Kislyuk et al., 2010).  However, it has bettered the final metrics somewhat with about a 2-5% 
reduction in the final number of contigs (data not shown).  The main reason that Velvet has 
been incorporated is that CG-Pipeline has been requested by users to be applied to Illumina 




The assembly stage has been modified at the combining stage.  For any assembly in CG-
Pipeline multiple assemblers may produce an assembly, and those assemblies are combined into 
a comprehensive assembly.  Different reference assemblies are not combined, nor are de novo 
with reference.  I have replaced Minimus with Minimus2 (Sommer et al., 2007).  We chose 
Minimus originally because it is a good short read assembler.  However, users encountered fatal 
problems due to its large memory usage.  We experimented with Minimus2 and found better 
memory usage i.e. no fatal problems due to memory usage, faster processing, and better 
resulting assemblies (unpublished data).  Fortunately, the incorporation of Minimus2 required 
very little change to the assembly pipeline code and was easily accomplished. 
The assembly stage has also been modified such that the best comprehensive assembly is 
chosen before continuing to feature prediction.  In this new paradigm, a user may choose 
multiple reference genomes for assembly.  The assembly stage will create an assembly against 
each reference genome in addition to a de novo assembly.  Thus the assembly stage will have 
multiple candidates as the best assembly: one de novo and one reference assembly per 
reference.  The best assembly is picked based on several standard assembly metrics: number of 
contigs, total bases assembled, average contig size, and N50.  N50 is defined as a size N such 
that 50% of the genome is contained in contigs of size N or greater.  This step of producing many 
assemblies and choosing of the best assembly is automated and does not require human 
intervention. 
FEATURE PREDICTION V0.2 
Feature prediction was performed in the genome using a suite of several programs. To 
predict genes, we used a combination of de novo and comparative methods. The Glimmer 
(Delcher et al., 1999) and GeneMark (Besemer et al., 2001) microbial gene predictors were used 




used for comparative prediction. Self-training procedures were followed for both de novo 
predictors, and the results, while highly concordant, were different enough (Table 4.4) to justify 
the inclusion of both algorithms. BLASTp alignment of all open reading frames (ORFs) at least 90 
nt long was performed using the Swiss-Prot protein database (Boeckmann et al., 2003). 
 
 
Table 4.4.  Prediction algorithm performance comparison and statistics (v0.2). Data for each strain are 
presented in rows. Prediction counts from the 3 standalone gene prediction methods are presented. Counts of 
protein-coding gene predictions reported by our algorithm and tRNA genes are also shown. Data presented are based 
on the automatic combined assemblies from Table 2. 





























M13220 2530 2725 1353 1325 974 2299 52 
M10699 2366 2494 1317 1284 826 2110 51 
M15141 2411 2578 1369 1343 841 2184 57 
M9261 2370 2553 1341 1308 802 2110 51 
M18575 2751 2927 1495 1448 1023 2471 63 
M5178 2377 2510 1315 1281 816 2097 52 
M15293 2062 2040 1285 1261 802 2063 51 
BBE001 4793 4793 2744 2732 2067 4799 48 
BBF579 4649 4646 2652 2635 2021 4656 48 
a
 Number of ORFs with protein-coding gene predictions where all 3 predictors agreed exactly or with a slight 
difference in the predicted start site.  
b
 ORFs where only 2 of the 3 predictors made a prediction.  
c 






Table 4.5.  Prediction algorithm performance comparison and statistics (v0.3). Data for each strain are 
presented in rows.  Counts of protein-coding gene predictions, rRNA genes, and tRNA genes are shown. 
Strain ID Total gene predictions 
reported 






M13220 2225 51 0 2174 
M10699 2194 51 0 2143 
M15141 2088 53 0 2035 
M9261 2134 51 0 2083 
M18575 2487 59 0 2428 
M5178 2300 54 1 2245 
M15293 2180 55 1 2124 
BBE001 4907 47 1 4859 





The results of these three methods were combined together using a combiner strategy 
outlined in Figure 4.4.  In this strategy, we first check that at least half of the predictors report a 
gene in a given ORF – in our configuration, 2 of the 3 predictors.  Then the Met (putative 
translation start) codon closest to the beginning of the BLAST alignment is found and declared to 
be the gene start predicted by BLAST.  We then find the gene start coordinate reported by the 
majority of the three predictors and report the resulting gene prediction. If no majority exists, 




Figure 4.4.  Schematics of combining strategy for prediction stage. BLAST alignment start, which may not coincide 




In addition to protein-coding gene prediction, ribosomal genes were predicted using 
alignment to a reference database of ribosomal operons, and tRNA genes were predicted using 
the tRNAScan-SE package (Lowe & Eddy, 1997). The results are summarized in Table 4.4. 
Results of the feature prediction stage are saved in a multi-extent GenBank formatted file. 
Features were named according to the following convention: contig-name_feature-id, 
where contig-name is as described earlier, and feature-id is a sequential zero-padded 
number unique to the feature across all contigs. For example, a gene with feature ID 1293 on 
contig 25 might have the name CDC_NME_M13320_025_1293. 
To validate the overall accuracy of the gene prediction stage of the pipeline, we ran our 
gene prediction tools on the genome of Escherichia coli K12, one of the best-annotated bacterial 
genomes (analysis described in Appendix B). Our pipeline was able to detect 95.7% of the 
annotated E. coli K12 protein-coding genes, and exactly predict starts in 85.5% of those.  50% of 
the E. coli predictions that report incorrect start codons report starts within 35 nt of the true 
start, and all reported starts are within 200 nt of the true start. 
FEATURE PREDICTION V0.3 
The feature prediction stage in CG-Pipeline is very robust.  However, we were able to 
increase its capabilities by incorporating rRNA prediction.  Here, we used RNAmmer (Lagesen et 
al., 2007).  RNAmmer uses hidden markov models to detect regions that likely belong to rRNA 
loci.  RNAmmer has been able to detect rRNAs with 100% specificity and sensitivity in four 
reference meningococcal genomes (data not shown).  With RNAmmer and the other feature 
predictors used in the pipeline (Altschul et al., 1997; Apweiler et al., 2010; Delcher et al., 1999; 
Lowe & Eddy, 1997; Lukashin & Borodovsky, 1998), feature prediction is able to detect >95% of 





FUNCTIONAL ANNOTATION V0.2 
Functional annotation of genome features was also performed using a combination of tools.  
Annotation of protein coding genes was based on an integrated platform that makes use of six 
distinct annotation tools, four of which employ intrinsic sequence characteristics for annotation 
and two that use extrinsic homology-based approaches to compare sequences against 
databases of sequences and structures with known functions. Information on Gene Ontology 
(GO) terms, domain architecture and identity, subcellular localization, signal peptides, 
transmembrane helices and lipoprotein motifs is provided for each protein coding gene (Figure 
4.5).  
BLASTp alignment of predicted proteins was performed against the UniProt database 
(Uniprot, 2009). Homology-based searches were also made across thirteen sequence and 
protein domain databases with the InterProScan suite (Mulder & Apweiler, 2007). Parsing of the 
results was carried out against the corresponding InterPro database. The pipeline also stores the 
top five hits for each gene against the NCBI non-redundant protein database, to provide 
potentially useful information. All homology searches were run locally. Signal peptides were 
annotated using the SignalP package (Bendtsen et al., 2004) and transmembrane domains were 
annotated with the TMHMM package (Krogh et al., 2001).  State of the art in subcellular 
localization algorithms was examined to ensure the best performance given our operational 
requirements. Insertion sequences (transposases) and proteins reported as virulence factors by 
VFDB (Chen et al., 2005; Yang et al., 2008) were also annotated.  These annotations of virulence-
related features make the pipeline particularly useful for projects working with pathogenic 




Figure 4.5.  Example functional annotation listing of a
shown including gene location, prediction and ann
properties, transmembrane helix presence, DNA and protein sequence. All names, locations, functional annotations 





n N.meningitidis gene in Neisseria Base. 









Table 4.6.  Feature annotation statistics (v0.2). Data for each strain are presented in rows. Data presented are 






























M13220 2299 326 
(14.2%) 
184 (8.0%) 10 (0.4%) 708 (30.8%) 603 
(26.2%) 
36 (1.6%) 
M10699 2110 310 
(14.7%) 
180 (8.5%) 5 (0.2%) 652 (30.9%) 577 
(27.3%) 
45 (2.1%) 
M15141 2184 317 
(14.5%) 
173 (7.9%) 16 (0.7%) 590 (27.0%) 583 
(26.7%) 
50 (2.3%) 
M9261 2110 303 
(14.4%) 
166 (7.9%) 13 (0.6%) 591 (28.0%) 558 
(26.4%) 
37 (1.8%) 
M18575 2471 349 
(14.1%) 
193 (7.8%) 13 (0.5%) 725 (29.3%) 668 
(27.0%) 
48 (1.9%) 
M5178 2097 298 
(14.2%) 
177 (8.4%) 3 (0.1%) 646 (30.8%) 572 
(27.3%) 
45 (2.1%) 
M15293 2063 304 
(14.7%) 
168 (8.1%) 6 (0.3%) 613 (29.7%) 567 
(27.5%) 
47 (2.3%) 
BBE001 4799 977 
(20.4%) 
368 (7.7%) 9 (0.2%) 807 (16.8%) 1184 
(24.7%) 
54 (1.1%) 
BBF579 4656 934 
(20.1%) 




 Total putative protein-coding sequences analyzed.  
b
 As predicted by SignalP (Bendtsen et al., 2004) ; percentage of total CDS indicated in parentheses.  
c
 As predicted by TMHMM (Krogh et al., 2001).  
d







Table 4.7.  Feature annotation statistics (v0.3). Data for each strain are presented in rows.  Annotations are 
















M13220 2174 268 (12.2%) 406 (18.5%) 730 (33.3%) 33 (1.5%) 
M10699 2143 255 (11.9%) 388 (18.1%) 679 (31.7%) 45 (2.1%) 
M15141 2035 243 (11.9%) 378 (18.6%) 673 (33.1%) 46 (2.3%) 
M9261 2083 256 (12.3%) 385 (18.5%) 684 (32.8%) 37 (1.8%) 
M18575 2428 276 (11.4%) 442 (18.2%) 788 (32.5%) 41 (1.7%) 
M5178 2245     
M15293 2124 251 (11.8%) 406 (19.1%) 680 (32.0%) 48 (2.3%) 
BBE001 4859     
BBF579 4840 868 (17.7%) 1015 (20.0%) 987 (20.4%) 45 (0.9%) 
 
a
 Total putative protein-coding sequences analyzed.  
b
 As predicted by SignalP (Bendtsen et al., 2004) ; percentage of total CDS indicated in parentheses.  
c
 As predicted by TMHMM (Krogh et al., 2001).  
d





After the functional annotations were determined, a naming scheme was employed for each 
locus to conform to standard annotation terminology. Specific gene names were assigned 
according to homology-based results. For genes that had a Uniprot result with a best hit at 
greater than 91% amino acid sequence identity and an e-value less than 1e-9, the gene assumed 
the best hit’s name. If the best hit had the keyword “hypothetical,” then we used a domain 
name from InterPro to name the gene. For example, if a gene was given the name 
“hypothetical” from Uniprot and a domain name of “transferase” from InterPro, then the final 
name was “hypothetical transferase protein.” Therefore most genes that were given 
“hypothetical” or “putative” prefixes could then be given a more comprehensive name based on 
further information such as domain names or protein functions. Genes with unknown functions 




other putative genes with unknown functions were given the name "putative uncharacterized 
protein."  
FUNCTIONAL ANNOTATION V0.3 
Previously, CG-Pipeline outputted several SQL files that represented the annotation output.  
Unfortunately for casual users of CG-Pipeline, these files are nonstandard, meant to be parsed 
by a computer, and are difficult for a person to read.  Therefore we added a tool to the 
annotation pipeline to compile a GenBank file from the output.  The GenBank file includes 
information from all annotations performed by CG-Pipeline: BLAST against the Uniprot database 
(Altschul et al., 1997; Apweiler et al., 2010), InterProScan (Zdobnov & Apweiler, 2001), TMHMM 
(Krogh et al., 2001), SignalP (Bendtsen et al., 2004), BLAST against the Virulence Factors 
Database (Chen et al., 2005; Yang et al., 2008), and the noncoding features, namely rRNA and 
tRNA.  The GenBank output file is comprehensive to all pipeline output and will include all future 
annotations that CG-Pipeline will make.   
Fortunately because the GenBank format is standard, the output from CG-Pipeline is 
portable, meaning that it can be imported into any other bioinformatics application.  For 
example, one potential use of the CG-Pipeline GenBank file is to upload it directly to a genome 
database such as NBase (Katz et al., 2010) or GenBank (Benson et al., 2010).  Thus the time from 
isolating a strain to sequencing it to publishing a GenBank file could be on the order of 1-2 
weeks.  See Table 4.7 for updated annotation metrics. 
AVAILABILITY 
The pipeline software package is available at our website (http://nbase.biology.gatech.edu). 
The package contains detailed instructions and scripts for installation of the pipeline and all 




which require large biological databases automatically download local copies of those databases 
upon installation. 
All of the N. meningitidis genomes reported here, along with custom annotations and tools 
for searching and comparative sequence analysis, are available for researchers online at our 
genome browser database (http://nbase.biology.gatech.edu). 
DISCUSSION 
GENOME BIOLOGY OF N. MENINGITIDIS AND B. BRONCHISEPTICA 
We have used the pathogen N. meningitidis for the majority of developmental and 
production testing of our pipeline. Although N. meningitidis gains no fitness advantage from 
virulence, it occasionally leaves its commensal state and causes devastating disease (Meyers et 
al., 2003). Several recent studies have used whole-genome analysis to determine the basis of 
virulence in this species but none have been conclusive (Hotopp et al., 2006; Perrin et al., 2002; 
Schoen et al., 2008).  With the recent advent of next-generation sequencing and the application 
of an analytical pipeline, such as presented here, this problem and other problems like it can be 
addressed in individual laboratories on a genome-wide scale. Here, we briefly speculate on a 
few of the implications of our findings for the genome biology of N. meningitidis to underscore 
the potential utility of our pipeline. 
Whole genome analysis of microbes has led to the development of the ‘pan-genome’ 
concept (Tettelin et al., 2005).  A pan-genome refers to the collection of all genes found within 
different strains of the same species.  An open pan-genome means that the genome of any 
given strain will contain unique genes not found within the genomes of other known strains of 
the same species. The extent to which microbial pan-genomes are open is a matter of debate 
(Lapierre & Gogarten, 2009). Recent studies have suggested that the N. meningitidis pan-




highly competent species (Chen & Dubnau, 2004; Kroll et al., 1998). We evaluated this 
hypothesis by finding the number of unique genes in each of the seven strains reported here 
along with seven previously published strains, using the results of our analytical pipeline. Our 
findings are consistent with (Schoen et al., 2008) in the sense that every genome sequence was 
found to contain at least 43 unique genes not found in any other strain. Thus, the N. 
meningitidis pan-genome does appear to be open. 
N. meningitidis is a human commensal that most often does not cause disease, and avirulent 
strains of the species are referred to as carriage strains. Results of previous comparative 
genomic analyses have been taken to suggest that carriage strains represent a distinct 
evolutionary group that is basal to a group of related virulent strains of N. meningitidis (Schoen 
et al., 2008). We tested this hypothesis using the results of our analytical pipeline applied to 
three carriage strains and eight virulent strains of N. meningitidis. Whole genome sequences 
were aligned and pairwise distances between genomes, based on nucleotide diversity levels, 
were compared within and between groups of carriage and virulent strains. We found that 
average of the pairwise genome sequence distances within (w) the carriage and virulent groups 
of strains was not significantly different from the average pairwise distances between (b) groups 
(w=0.074±0.027 b=0.090±0.014, t=0.693, P=0.491). This result is inconsistent with the 
previously held notion that carriage and virulent strains represent distinct evolutionary groups 
based on whole genome analysis. However, our findings are consistent with earlier work that 
found little genetic differentiation between carriage and virulent strains of N. meningitidis 
(Jolley, et al., 2005). 
Currently, there is no unambiguous molecular assay to distinguish B. bronchiseptica from 
other Bordetella species. One reason the two B. bronchiseptica genomes reported here were 




Bordetella species) to facilitate the development of a B. bronchiseptica-specific PCR assay. To 
identify such genes, we performed BLASTn with B. bronchiseptica query genes uncovered by our 
pipeline against other B. bronchiseptica strain genomes along with four genomes of closely 
related Bordetella species. We uncovered a total of 223 genes that are present in all B. 
bronchiseptica strains and absent in all other Bordetella species.  To narrow down this set of 
potential PCR assay targets, we searched for the most conserved B. bronchiseptica-specific 
genes. As a point of reference, we determined the sodC gene used in the N. meningitidis-specific 
PCR assay (Kroll et al., 1998) to be 99.6% identical among all six completely sequenced strains of 
N. meningitidis.  There are seven B. bronchiseptica-specific genes with ≥99.6% sequence 
identity; these genes represent a prioritized list of potential PCR assay targets. 
COMPUTATIONAL GENOMICS PIPELINE 
We have presented our computational genomics pipeline, a local solution for automated, 
high-throughput computational support of prokaryotic genome sequencing projects. While the 
revolution in sequencing technology makes possible the execution of genome projects within 
individual laboratories, the computational infrastructure to fully realize this possibility does not 
yet exist.  We made a comprehensive effort to put the tools required for this infrastructure into 
the hands of biologists working with next-generation sequencing data.  Our aim in the course of 
this project was to facilitate decentralized biological discoveries based on affordable whole-
genome prokaryotic sequencing, a mode of science termed ‘investigator-initiated genomics’.  
For example, one project enabled by the pipeline in our laboratory is a platform for SNP 
detection and analysis in groups of bacterial genomes. 
One of our major goals was to provide full automation of our pipeline’s entire workflow, and 
this has been achieved.  On the other hand, to allow computationally savvy users to realize the 




strike a balance between these objectives, and provide a modular, hierarchically organized 
structure to permit maximum customization when so desired. 
The state of the art in prokaryotic computational genomics moves at a formidable pace.  The 
modular organization of our pipeline, along with the emphasis on integration of complementary 
software tools, allows us to continually update our platform to keep pace with developments in 
computational genomics.  For instance if a new, better assembler becomes available, we can 
include its results in the assembly stage with a simple change to the pipeline code. 
CG-Pipeline has been in made available to the public since June 2010.  Since then, several 
institutions have used it to analyze countless genomes.  Those institutions that use CG-Pipeline 
and are known to us are: Jordan Lab at Georgia Institute of Technology and MVPDB (ourselves), 
Pacific Biosciences, National Biodefense Analysis and Countermeasures Center under the 
Department of Homeland Security, The Hong Kong Bioinformatics Centre, the core facilities at 
both CDC and Emory University, the University College Dublin, Scottish Crop Research Institute, 
and the Spain and Konstantinidis labs at the Georgia Institute of Technology.  Internally in our 
collaboration between the CDC Meningitis and Vaccine Preventable Diseases Branch and The 
Jordan Lab, we have analyzed 23 N. meningitidis and B. bronchiseptica genomes.  Thus the 
distribution and usage of CG-Pipeline is growing rapidly.  
FUTURE UPDATES 
CG-Pipeline is continuously being developed.  As CG-Pipeline is modular, so are the updates 
for it.  Installation for CG-Pipeline is automated.  It places its executable scripts into an 
appropriate directory, downloads appropriate databases, and formats the databases as 
appropriate.  However, we have noted that on some machines, installation might crash due to 
local customizations or different versions of prerequisite software.  To address these cases, we 




particular software package, the script will provide brief instructions on how to obtain it.  
Secondly we will modify the installation script such that it will resume where it stopped in the 
case of a crash.  One major reason for these crashes has been a reinvention of BLAST called 
BLAST+ which is quickly becoming standard and has different executables (Camacho et al., 
2009).  CG-Pipeline will accommodate BLAST+ to avoid such crashes in the future. 
Some users of CG-Pipeline have requested that Illumina data be valid input in addition to 
454 SFF files.  In response we have begun development for the incorporation of the Velvet 
(Zerbino & Birney, 2008) and Bowtie (Langmead et al., 2009) short read assemblers.  The 
assemblies from these programs will be incorporated into a combining stage as earlier 
described. 
Although Minimus2 is a more optimal solution than most other combining tools, the 
combining stage can be optimized.  Using an assembler like Minimus2 results in an inherent 
flaw.  In the combination of two assemblies, a given read might be overrepresented and might 
bias an assembly output, or, a single read might be represented in two different locations.  We 
have noted a tool specifically for the combination of two assemblies called the Reconciliator 
(Zimin et al., 2008).  In short, this tool detects disagreements between two assemblies (e.g. from 
AMOS and Newbler) and attempts a reassembly at these confounding sites.  This represents the 
best method of combining two assemblies and is a necessity for the future of CG-Pipeline.  
Although the feature prediction stage currently predicts with more than 95% accuracy, we 
have some improvements that can be made.  It was noted that RNAmmer predicts start and 
stop sites within 0 to 9 nt of the correct sites.  Using BLAST to fine-tune these start and stop 
sites would increase the overall accuracy of rRNA prediction.  Furthermore BLAST would give 




rRNA curation site such as the Ribosomal Database Project (Cole et al., 2009).  Secondly for the 
prediction stage, coding sequence prediction accuracy can be increased if a Gibbs sampler were 
used.  Gibbs sampling is a useful step for GeneMark (Lukashin & Borodovsky, 1998), which will 
help in finding start sites in coding sequences by training GeneMark’s hidden markov model. 
Feature Annotation can be made better by introducing subcellular localization.  To that end, 
many packages offer some predictions (Bendtsen et al., 2004; Krogh et al., 2001; Yu et al., 2010).  
However, one group has already created a decision-making tree using these tools and more for 
subcellular prediction (Emanuelsson et al., 2007).  We plan to incorporate this algorithm such 
that CG-Pipeline will be capable of subcellular localization.  Subcellular localization is an 
important annotation.  One example is the prediction of all surface antigens on a pathogen’s 
surface, such that vaccine targets can be predicted—a process called reverse vaccinology 
(Rappuoli, 2000).  One last improvement will be to incorporate genome-wide statistics.  For 
many genome projects, it is an important task to categorize the functions of all genes, usually by 
Gene Ontology (GO) or Clusters of Orthologous Genes (COGs) (Ashburner et al., 2000; Tatusov 
et al., 2003).  Therefore we will create an inventory of ratios of genes for each category in GO or 
COGs at the end of the annotation stage.  Additionally, genome statistics at each of the three 
stages will be outputted with information such as the total number of coding genes, noncoding 
genes, and assembly statistics (e.g. number of contigs). 
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NEISSERIA BASE: A COMPARATIVE GENOMICS DATABASE 
FOR NEISSERIA MENINGITIDIS 
ABSTRACT 
Neisseria meningitidis is an important pathogen, causing sudden and life-threatening 
diseases including meningitis, septicemia and in some cases pneumonia.  Genomic studies hold 
great promise for the future of N. meningitidis research, but substantial database resources are 
needed to deal with the wealth of information that comes with completely sequenced and 
annotated genomes.  To address this need, we introduce Neisseria Base (NBase), which is a 
comparative genomics database and genome browser that houses and displays all publically 
available N. meningitidis genomes.  In addition to existing N. meningitidis genome sequences, 
we sequenced and annotated 19 new genomes using 454 pyrosequencing and the CG-Pipeline 
genome analysis tool.  In total, NBase hosts 27 complete N. meningitidis genome sequences 
along with their associated annotations.  The NBase platform is designed to be scalable, via the 
underlying database schema and modular code architecture, such that it can readily incorporate 
new genomes and their associated annotations.  The front page of NBase provides user access 
to these genomes through searching, browsing and downloading.  NBase search utility includes 
BLAST based sequence similarity searches along with a variety of semantic search options.  All 
genomes can be browsed using a modified version of the GBrowse platform, and a plethora of 
information on each gene can be viewed using a customized details page.  NBase also has a 
whole-genome comparison tool that yields single nucleotide polymorphism (SNP) differences 




be used to address biological questions, we have compared ST-11 genomes against other 
genomes to identify markers. 
Database URL: http://nbase.biology.gatech.edu 
INTRODUCTION 
MENINGOCOCCAL DISEASE 
Neisseria meningitidis is a gram-negative encapsulated bacterium that is a leading 
worldwide cause of bacterial meningitis (Rosenstein et al., 2001).  Meningococcal meningitis and 
sepsis can cause death within hours and are particularly lethal in young children and 
adolescents.  Meningitis case fatality rates range from 10 to 14%, and many survivors have long 
term neurological sequelae such as deafness and mental retardation.  Each year, there are two 
to three thousand cases of meningococcal meningitis in the United States with about a 10% case 
fatality rate.  Understanding the genomics of circulating strains is important for understanding 
the population biology of N. meningitidis.  For example, a recent database BIGSdb takes 
advantage of loci across the meningococcal genome to produce customizable molecular profiles 
which reveals high-quality resolution typing data (Maiden & Jolley, 2010).  Our needs include 
searching whole genomes for genomic determinants for phenotypic differences between 
isolates.  To meet our needs, the Meningitis Laboratory at the Centers for Disease Control and 
Prevention has adopted a genomics approach to the study of N. meningitidis.   
GENOMICS AND BIOINFORMATICS FOR N. MENINGITIDIS  
There are a number of efforts underway to characterize N. meningitidis genome sequences, 
and the amount of genomic data for this organism will increase exponentially in the near future.  
CDC recently used next-generation sequencing technology (Margulies et al., 2005) to 
characterize 19 N. meningitidis genomes, and at the time of this writing there are 9 additional N. 




Kislyuk et al., 2010; Parkhill et al., 2000; Peng et al., 2008; Rusniok et al., 2009; Schoen et al., 
2008; Tettelin et al., 2000).   
It is essential to develop bioinformatics tools that can handle these data and have the 
capacity to scale sufficiently to accommodate the coming flood of N. meningitidis genome 
sequences.  It is also important to provide computational genomics applications that are 
accessible and useful to working biologists.  Our group has previously addressed one aspect of 
these challenges via the development of a fully automated analytical pipeline that takes genome 
sequence data and sequentially performs genome assembly, gene prediction and functional 
annotation – the CG-pipeline (Kislyuk et al., 2010).  This allows investigators to gain rapid access 
to annotations for individual N. meningitidis genomes without laborious manual analysis.  
However, once such data are in hand, researchers will still need a way to visualize the 
information and to compare annotation data and sequences among different genomes.  For 
example, it could prove informative to compare genome sequences between strains of N. 
meningitidis with distinct disease causing capacities or between isolates from different 
outbreaks.  It will also be critical to develop and maintain a shared platform for the storage and 
dissemination of the data and results generated by the N. meningitidis genome projects.  To 
address these aims, we have developed Neisseria Base (NBase), an online platform for the 
storage, dissemination and comparative analysis of N. meningitidis genomes characterized at 
CDC and elsewhere.  NBase allows users to browse, search and download genome sequences 
and annotations for N. meningitidis.  The database also includes comparative genome analysis 
applications including the ‘SNPtool’ that allows users to discover individual nucleotide variations 
that distinguish between user-selected groups of N. meningitidis genomes.  We show an 
example whole genome comparison in this manuscript.  The NBase platform is designed to be 




annotations.  NBase is a freely available community resource that can be found at 
http://nbase.biology.gatech.edu. 
MATERIALS AND METHODS 
GENOMIC DATA 
A total of 19 N. meningitidis genomic sequences were characterized via 454 pyrosequencing 
at CDC Biotechnology Core Facility Branch and analyzed at Georgia Tech.  An additional 8 
previously characterized N. meningitidis genomes are also included in NBase.  A list of the 
genomes in NBase, along with metadata describing their origins, can be found in Table C.1.  
Genomic sequence data characterized at CDC were analyzed using the CG-Pipeline (versions 
0.2.1 to 0.2.4) automated genome analysis platform.  The CG-Pipeline was previously developed 
by our group for the automated assembly and annotation of prokaryotic genome sequences 
(Kislyuk et al., 2010), and it is freely available at http://nbase.biology.gatech.edu.  During the 
assembly stage the best reference genome assembly or best de novo assembly was chosen for 
further analysis.  On the resulting assembly, gene locations were predicted using a combination 
of homology searches and ab initio methods.  On those gene predictions, we performed 
automated functional annotation using a combined approach that includes 17 different 
annotation applications.  The annotation step produces GenBank format flatfiles, and these 
GenBank files are converted into general feature format (GFF) for import into NBase.  Further 
details of the genome sequencing protocol and the genome analysis procedures can be found in 
the report on the CG-Pipeline (Kislyuk et al., 2010).   
SOFTWARE COMPONENTS 
To construct NBase, we used several software components: GBrowse 2.00 (Stein et al., 
2002), BLAST version 2.2.17 (Altschul et al., 1997), Perl 5.8.8, BioPerl 1.6.1. (Stajich et al., 2002), 




2004; Waterhouse et al., 2009).  NBase rests on MySQL version 5.0 and is hosted using the 
Apache version 2.0 web server application (http://mysql.com, http://apache.org). 
MULTIPLE SEQUENCE ALIGNMENT 
Whole genome multiple sequence alignments (MSAs) were constructed from 27 genomes (Table 
C.1) using the program MAUVE with default settings.  MAUVE produces local alignments of co-
linear orthologous regions, shared among all genomes, which are called local co-linear blocks 
(LCBs).   Each individual LCB was aligned further using the program MUSCLE, without using the 
refine option. 
DETERMINATION OF SEQUENCE TYPES 
Sequence types (STs) for some new genomes were determined by conventional sequencing 
methods (Maiden et al., 1998).  However for most new genomes because 454 pyrosequencing 
had already been performed, STs were determined using the whole genome sequence.  Whole 
genomes were compared against the PubMLST database (Jolley et al., 2004) to find and perform 
allele calls for all seven loci.  The only ambiguous sequence was adk from M16917, which was 
resequenced to confirm its identity.  Otherwise there were no novel alleles and no imperfect 
matches for these genomes. 
COMPARISON OF ST-11 GENOMES AGAINST OTHER GENOMES 
ST-11 genomes FAM18, M13519, M16917, M17661, M18774, M15141, and M9261 were 
placed into group 1.  All other genomes in NBase were placed into group 2: Z2491, M13220, 
α14, α153, α275, M11791, M17094, M10699, M15293, M5178, MC58, M16207, 8013, M17062, 
M20899, M14900, M18575, 053442, M17277, and M20918 (Table C.1).  MC58 was used as a 
reference genome.  These groups of genomes were used in SNPtool (Figure 5.2), which in turn 
yielded SNPs that discriminate genomes between the two groups.  These discriminating SNPs 






The NBase front page serves as the gateway to all of the data, tools and analytical capability 
housed in NBase.  The front page of NBase is designed to be straightforward.  The user may 
choose to do one of several things from the front page: 1) view metadata, 2) download, 3) 
browse, 4) search, or 5) perform single nucleotide polymorphism (SNP) analysis. 
Metadata, the information about each genome, is located on the left navigation bar (Figure 
5.1C).  Information about each isolate, such as geographic origin, date isolated, and profile 
information is shown in columns.  Genomic data is available here to download in standard file 
formats (GenBank, FASTA, GFF).  In addition, all software generated by this comprehensive 
project including the CG-Pipeline can be downloaded from the home page.  On the Alignment 
Viewer page, the multiple sequence alignment of all available genomes may be viewed per LCB 
by either reading the plain text in Clustal format or using the Jalview applet (Clamp et al., 2004; 
Waterhouse et al., 2009).  Jalview includes functions for generating phylogenetic trees on 
demand, which is useful for observing the similarity between strains in a specific region. 
 
 
Figure 5.1.  The Front Page Sidebar.
metadata.   (A) To browse, users can select a genome and a contig to proceed to the GBrowse interface.  (B) To search 
a user can supply a keyword or can choose to search via one of several search items.  (C) Genomic metadata is 
available via the Organism Data link (See Table
 
 
Users can browse genomes by selecting the organism from the drop
sidebar (Figure 5.1A).  After a genome has been selected, available contigs or chromosomes are 
shown.  Most 454 assemblies will not be complete due to coverage considerations 
Waterman, 1988) or due to repeat elements 
genomes on NBase are viewable on the contig level instead of a chromosomal level.  After the 
contig or chromosome is chosen, the user is brought to the GBrowse 
graphical interface (see Genome Browser section).
Another way to arrive at the GBrowse interface is to search for specific genomic features.  In 
this case, genomic features are any a
associated annotations.  Categories of searches are located on the sidebar on the Search page 
(Figure 5.1B).  Search results may be filtered to selected organisms, feature types (
and/or annotation source.  The annotation sources correspond to different annotation 
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applications used in the CG-Pipeline genome analysis tool (Kislyuk et al., 2010).  Each specific 
type of search allows for the inclusion of more specific parameters such as gene length.  If a user 
does not want to use a specific search, a general keyword search is provided.  One more way to 
search for genomic sequences is to use any one of the five BLAST programs in the BLAST 




Figure 5.2.  SNPtool.  SNPtool finds discriminating SNPs between two groups of genomes.  Each group is defined 
by the user, by dragging each genome to a designated group.  Not all genomes must be used.
must be designated, as the results can be viewed on the graphical genome browser from the vantage point of the 
chosen reference genome.  Invasive isolates are designated by red, carried by blue.
 
 
The user may navigate to the SNP ana
top of the front page.  SNPtool uses a comprehensive multiple sequence alignment (MSA) to 
discover SNPs that show mutually exclusive patterns between two groups of genomes 
5.2).  Such SNPs serve as markers for discriminating between the two groups of genomes.  To 
use SNPtool, a user drags desired genomes into the first or second group to define each group.  
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Next, the user supplies a reference genome so that the results can be visualized in the GBrowse 
interface.  The SNPtool outputs the coordinates of all discriminating SNPs, defined in the 
genome space of the reference genome, along with a list of genes associated with the 
discriminating SNPs.  These SNP genes are defined as genes that have discriminating SNPs within 
their coding regions or within +/- 1kb of the predicted coding start/stop sites.  All results from 
previous SNPtool selections are accessible by a hyperlink on the SNPtool page, and the user can 
view selected results in the Genome Browser. 
GENOME BROWSER 
We chose to use GBrowse because it is customizable, open-source, fast, and reliable (Stein 
et al., 2002).  Also it is a proven genome browser used by several institutions for several other 
organisms and so many users are familiar with the interface (Bieri et al., 2007; Drysdale, 2008; 
Elsik et al., 2006) (GMOD Users, http://gmod.org/wiki/GMOD_Users).  GBrowse works with a 
MySQL database, using the GFF schema.  We were able to use this schema unmodified to store 
multiple genome annotations in a single database and quickly load the feature annotations with 
GBrowse.  Use of this approach also facilitates scalability with respect to rapid and facile 
assimilation of new genome sequences and annotations.   
NBase is also designed to be scalable with respect to the addition of new applications.  This 
has been achieved via the formatting of the database schema that underlies GBrowse.  
Currently, all of our search utilities, both text and sequence based, query the same MySQL 
database on which GBrowse runs.  When any new applications are added to the site, they will 
be designed to query the same database with little or no modification to the schema.  
Furthermore, all of the source for the browser and associated utilities has a modular design to 




GBrowse gives the user a linear map of a selected region of a genome with the genomic 
features appearing at their respective coordinates (Figure 5.3).  The user can zoom in and out, 
move upstream and downstream along the sequence, and configure the display of sequence 
features.  GBrowse uses semantic viewing which refers to how much detail is shown when the 
depiction is zoomed in or zoomed out.  From a distance, features are shown only as colored 
arrows which show directionality.  At a medium zoom, features’ names are visible.  At a very 




Figure 5.3.  Genome Depiction. 




Genes, nucleotides, and residues can only be viewed if their respective tracks have been 
turned on.  Additionally users can supply their custom tracks to overlay and compare features, 
using the correct file format 
results from SNPtool.  The results of SNPtool, the lists of discriminating SNPs and SNP genes, can 
be uploaded to NBase and compared to other tracks 
DETAILS PAGE 
Clicking on a feature brings the user to a details 
has some fundamental characteristics that will be displayed: name, length, and coordinates.  For 
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 The genome is represented linearly, with features on their respective 
heir own details page.  (B) Uploaded 
(Figure C.1).  One example of adding custom tracks is using the 
(Figure 5.3). 





data that is produced by the CG-Pipeline or that is already present in imported genomes, there 
is a wealth of additional information available.  The CG-Pipeline annotates genes using the 
UniProt database (2010) and InterProScan (Mulder & Apweiler, 2007).  In addition, it predicts 
transmembrane helices with TMHMM (Krogh et al., 2001), signal peptides with SignalP 
(Bendtsen et al., 2004), and virulence genes with the virulence factors database (Chen et al., 
2005; Yang et al., 2008).  All of these annotations are present in NBase.  The details page 





Figure 5.4.  Details Page.
feature types may appear: gene, protein, protein domain, signal peptide, and transmembrane structure.  The target 
feature is highlighted in yellow.  The nucleotide and amino acid sequences for this feature appear at the bottom of 
the page.  All features on the page include links to their coordinates in GBrowse genome viewer.
 
BIOLOGICAL DISCOVERY
Here, we illustrate the potential application of NBase, and the comparative genomics utility 
encoded therein, to biological discover
SEQUENCE TYPE 11 
To molecularly profile and type meningococci, multilocus sequence typing (MLST) is used 
(Maiden et al., 1998).  In MLST, seven predefined loci are sequenced and their alleles
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Those allele calls are concatenated to produce a profile called a sequence type (ST).  At the time 
of this writing, several hundred alleles are defined per locus, and more than 8,500 STs are 
defined (Jolley et al., 2004). 
Since its inception, MLST has been used to define the population structure of N. 
meningitidis.  Consequently, some STs have been correlated with phenotype, especially those 
correlated with disease.  One influential study found that ST-11 meningococci are more 
associated with disease than any other ST (Yazdankhah et al., 2004).  We compared all available 
ST-11 meningococcal genomes against all other available genomes (Table C.1).  The aim of this 
analysis is to show markers for ST-11 outside of the seven predefined loci of MLST (Maiden et 
al., 1998).  Whole genome comparison yielded 2,589 SNPs that show mutually exclusive 
patterns between ST-11 genomes and all others available to us.  All of these markers represent 
possible markers for ST-11, which by definition could detect ST-11 apart from other STs.  While 
MLST is used on a kilobase magnitude, this SNP analysis represents a resolution at 3 fold finer 
magnitude and could be used to find smaller regions or even nucleotides that distinguish an ST 
from another.  This is a proof-of-principle that shows that the SNPtool is able to identify 
differences between groups of genomes at a very fine nucleotide resolution.  Theoretically the 
SNPtool could also be used to match phenotypes to genotypes.  For instance, if the genomes of 
all fast-growing meningococci were compared against slow-growing meningococci then markers 
for its growth, and even putatively causative genes, could be identified. 
DISCUSSION 
Although there are other neisserial databases, e.g. (Aurrecoechea et al., 2007; Dehal et al., 
2010; Flicek et al., 2010; Kent et al., 2002; Sayers et al., 2010), NBase is customized for the CG-
Pipeline (Kislyuk et al., 2010).  Other genome browsers have great strengths, especially 




when viewing genomes, and contains mutagenesis studies for genome 8013 (Geoffroy et al., 
2003).  However, NBase is the genome browser that can easily accommodate new genomes that 
are analyzed using the CG-Pipeline, which is open source and can run locally on a desktop 
computer.   
Using only open source software has many advantages.  First, the GBrowse interface is 
familiar to many, and so the learning curve is lessened.  Second, all new plugins for GBrowse are 
readily incorporated into NBase as needed (e.g. a plugin to download a selected region of a 
genome).  Third, all software belonging to the Generic Model Organism Database project 
(GMOD) can be assimilated into NBase.  For example in the future, we will be incorporating 
GMOD’s SynView which is a synteny viewer for GBrowse (Wang et al., 2006).   
NBase allows searching, browsing, and downloading of whole genomes (including 
assemblies and annotations).  In total we have 27 meningococcal genomes available for these 
tasks.  At NBase’s core is GBrowse which has a simple, yet sophisticated, database structure and 
which has a graphical interface for browsing genomes.  GBrowse also facilitates the usage of a 
details page for each feature in a genome so that, not only does a user see the breadth of a 
genome, but the user can also see depth.  Finally, we have demonstrated the malleability and 
scalability of NBase by incorporating a custom tool, SNPtool.  SNPtool compares two groups of 
genomes and displays discriminating SNPs and their associated SNP genes.  Furthermore, we 
have demonstrated that SNPtool can be used to compare whole groups of isolates on a genomic 
level to uncover individually significant SNPs.  This has been useful for uncovering genomic 
markers for ST-11.   
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USING SNPS TO DISCRIMINATE DISEASE ASSOCIATED 
FROM CARRIED GENOMES OF NEISSERIA MENINGITIDIS 
ABSTRACT 
Neisseria meningitidis is one of the main agents of bacterial meningitis causing substantial 
morbidity and mortality worldwide.  However, most of the time N. meningitidis is carried as a 
commensal not associated with invasive disease.  The genomic basis of the difference between 
disease associated versus carried isolates of N. meningitidis may provide critical insight into 
mechanisms of virulence, yet it has remained elusive.  Here, we have taken a comparative 
genomics approach to interrogate the difference between disease associated and carried 
isolates of N. meningitidis at the level of individual nucleotide variations (i.e., SNPs).  We aligned 
complete genome sequences of 8 disease associated and 3 carried isolates of N. meningitidis to 
search for SNPs that show mutually exclusive patterns of variation between the two groups.  We 
found 801 SNPs that distinguish the 8 disease associated from the 3 carried genomes of N. 
meningitidis, which is far more than can be expected by chance alone given the level of 
nucleotide variation among the genomes.  The putative list of disease associated versus carriage 
discriminating SNPs may be expected to change with increased sampling or changes in the 
identities of the isolates being compared.  Nevertheless, we show that these discriminating SNPs 
are more likely to reflect phenotypic differences than shared evolutionary history.  
Discriminating SNPs were mapped to genes and the functions of the genes were evaluated for 
possible connections to virulence mechanisms.  A number of over-represented functional 
categories related to virulence were uncovered among SNP genes including: oxidoreductases, 





Neisseria meningitidis, the meningococcus, is a leading cause of bacterial meningitis 
worldwide with devastating morbidity and mortality (Centers for Disease Control and 
Prevention [http://www.cdc.gov/meningitis/about/faq.html]).  N. meningitidis is a gram-
negative encapsulated diplococcus of the human nasopharynx that is most frequently found to 
be asymptomatically carried (Maiden & Caugant, 2006); ~10% of healthy individuals are carriers 
of N. meningitidis (Claus et al., 2005; Dolan-Livengood et al., 2003).  In a small number of 
carriers, some strains of N. meningitidis are able to invade epithelium of the nasopharynx and 
enter the bloodstream, thus leading to invasive disease, such as meningococcal meningitis and 
meningococcemia (Rosenstein et al., 2001). 
A number of previous studies have taken a comparative genomics approach to try and 
determine if there is any genomic basis for the difference between disease associated and 
carried isolates of N. meningitidis.  Perrin et al. (2002) used comparative genome hybridization 
(CGH) to compare the genomes of disease associated N. meningitidis strains against the 
genomes of the closely related species N. gonorrhoeae and N. lactamica (Perrin et al., 2002).  
They were able to find a number of chromosomal regions present only in N. meningitidis, 
suggesting a possible role in species-specific virulence.  However, genes found in the species-
specific regions would later be shown to be present in both disease associated and carried 
isolates of N. meningitidis (Schoen et al., 2008).  A subsequent CGH study discovered 55 genes 
present in all N. meningitidis serogroup B isolates analyzed and absent in Neisseria commensal 
species (Stabler et al., 2005).  Nevertheless, several of these serogroup B strains were carried 
isolates that were not associated with disease.  It was also shown later that the majority of 
genes previously implicated in virulence using the comparative approach were shared between 




In 2005, Bille et al. discovered an 8kb bacteriophage-derived sequence shared among 29 
disease associated N. meningitidis genomes and largely absent from carried isolates (Bille et al., 
2005).  While no single gene in this prophage met the condition of being present in all disease 
associated genomes and absent in all carried genomes, the distribution of prophage genes was 
highly skewed towards disease associated genomes.  Thus, at that time, this genetic island 
represented the best example of a genomic feature that could distinguish disease associated 
from carried genomes of N. meningitidis.  However, the next year Hotopp et al. used a more 
exhaustive CGH study to show that this prophage was actually found in the genomes of 60% of 
disease associated isolates and 42% of carried isolates (Hotopp et al., 2006).    
In 2008, Schoen et al. performed the first complete genome sequence based comparison 
between disease associated and carried isolates of N. meningitidis (Schoen et al., 2008).  These 
authors found that genes previously implicated in virulence were widely shared among disease 
associated and carried genomes; in other words, there does not appear to be any core 
pathogenome for N. meningitidis.  Later, the same group used genome sequence comparison 
between a disease associated versus a carried isolate of serogroup B N. meningitidis strains, to 
show that virulence in N. meningitidis is likely to be encoded by sequence differences found 
across numerous genes (Joseph et al., 2010).  Taken together, the results of all of these 
comparative genomic studies indicate that the presence or absence of specific genes, sets of 
genes, or other large-scale genomic features cannot be used to distinguish disease associated 
from carried isolates of N. meningitidis.  
In light of these previous results, we decided to explore the utility of individual nucleotide 
variations for discriminating between disease associated versus carried isolates of N. 
meningitidis.  The use of nucleotide variation takes advantage of advances in sequencing 




that single nucleotide polymorphisms (SNPs) will provide markers that can distinguish disease 
associated from carried isolates of N. meningitidis.  To test this hypothesis, we compared 
complete genome sequences of 8 disease associated (Bentley et al., 2007; Kislyuk et al., 2010; 
Parkhill et al., 2000; Peng et al., 2008; Tettelin et al., 2000) and 3 carried isolates (Schoen et al., 
2008) of N. meningitidis.  The disease associated isolates were sampled from individuals with 
meningococcal disease, and the carried isolates were taken from asymptomatic individuals.  
Thus, the two groups of isolates represent instances of phenotypic differences in N. meningitidis 
virulence, and we sought to assess whether there may be genomic determinants of these 
differences.  To do this, we searched for SNPs that show mutually exclusive patterns of variation 
between the two groups of isolates.  We found that hundreds of SNPs can serve as markers that 
distinguish these sets of disease associated versus carried isolates of N. meningitidis, and these 
discriminating SNPs are more likely to reflect phenotypic differences than shared evolutionary 
history.  We mapped these discriminating SNPs to N. meningitidis genes to assess their potential 
functional significance.   
The transition from asymptomatic to disease associated states for N. meningitidis may be 
extremely rapid.  Carried isolates studied here belong to a serogroup and ST combination that 
has been shown to cause a small percentage of meningococcal disease and isolates from disease 
associated strains spend most of their time being carried.  Thus, the disease associated versus 
carried isolates studied here yield a snap-shot in time and place of a set of nucleotide variants 
that distinguish one group of N. meningitidis disease associated isolates from a group of carried 
isolates.  Accordingly, the particular set of discriminating SNPs characterized here, along with 
the list of SNP genes, will likely change as additional genome sequences are characterized and 





MATERIALS AND METHODS 
N. MENINGITIDIS CULTURE CONDITIONS AND DNA EXTRACTION   
Isolates were stored at -80°C in defibrinated sheep blood (Lampire, Pipersville, 
Pennsylvania) prior to use, and were subsequently streaked onto Chocolate II Agar (BBL, Sparks, 
Maryland) and incubated at 37°C overnight with 5% CO2 before harvesting for DNA 
preparation.  Purified genomic DNA was extracted using the Blood and Cell Culture DNA Maxi Kit 
(Qiagen, Valencia, California) following the manufacturer’s instructions.  The DNA concentration 
and the 260/280 ratio was obtained using a NanoDrop ND-1000 Spectrophotometer (NanoDrop 
Products, Wilmington, Delaware).   
GENOME SEQUENCING AND ANALYSIS   
Sequencing of N. meningitidis isolates M9261, M13220, M10699, and M15141 was 
performed using Roche Applied Science/454 pyrosequencing in the CDC Biotechnology Core 
Facility; each strain was sequenced using the GS-20 platform.  For each genomic DNA 
preparation, a random shotgun library was produced using Roche protocols for nebulization, 
end-polishing, adaptor ligation, nick repair and single-stranded library formation (Margulies et 
al., 2005).  Following emulsion PCR, DNA bound beads were isolated and sequenced using long 
read (LR) sequencing kits.  Sequencing was followed by read trimming and refiltering to recover 
short quality reads.  
Genome sequence assemblies were performed using a customized genome analysis pipeline 
(CG-pipeline version 0.2.1)  (Kislyuk et al., 2010) that combines reference based assembly using 
the Newbler assembler and AMOScmp (Pop et al., 2004).  Results from the two assemblers were 
combined using Minimus.  The analytical pipeline was also used to perform gene prediction and 




were uploaded into a customized database, Neisseria Base (NBase), based on the GBrowse 
platform (Stein et al., 2002). 
GENOME ALIGNMENT AND SNP ANALYSIS 
The four N. meningitidis isolates characterized here were analyzed together with 7 other 
completely sequenced N. meningitidis isolates (Table 6.1).  Complete genome sequences were 
aligned using the program MAUVE, which locates and aligns conserved and syntenic genomic 
regions called local colinear blocks (LCBs) (Darling et al., 2004).  Default MAUVE alignment 
settings were used with the exception of a minimum LCB weight of 500.  M13220 was set as the 
reference genome, whereby all other genomes were rearranged according to M13220.  Only 
LCBs that contained conserved regions of all 11 isolates (n=69) were used for subsequent SNP 
analysis.  The 69 individual LCBs were re-aligned using ClustalW (version 1.83) (Thompson et al., 
2002).  LCB alignments were analyzed to look for discriminating nucleotide patterns (i.e. SNPs) 
separating the 8 disease associated genomes from the 3 carried genomes (Table 6.1).  The 
disease associated isolates were sampled from individuals with meningococcal disease and the 
carried isolates were taken from asymptomatic individuals.  Here, SNPs include nucleotide 
variations along with insertions and deletions (indels).  A discriminating SNP is defined as a 
polymorphic site that shows one nucleotide pattern for one group of genomes (disease 
associated or carried), and a mutually exclusive pattern for the other group (Figure 6.1).  The 
total number of disease associated versus carried SNPs was computed and compared to a null 
distribution of expected discriminating SNP counts, given the background polymorphism level, 
generated using simulation.  For simulation, the identity of the nucleotides at each polymorphic 
site were randomly permuated among genomes.  Polymorphic sites were then evaluated to 












Location (year) Accession 
M13220 A ST-7 ST-5 Disease  Phillipines (2005) SRS074220 
M10699 B ST-32 ST-32 Disease  Oregon (2003) SRS074512 
M15141 C ST-11 ST-11 Disease  New York (2006) SRS074514 
M9261 W135 ST-11 ST-11 Disease  Burkina Faso (2002) SRS074515 
053442 C ST-4821 ST-4821 Disease  China (2003) CP000381 
Z2491 A ST-4 ST-4 Disease  Gambia (1983) AL157959 
FAM18 C ST-11 ST-11 Disease  North Carolina (1980s) AM421808 
MC58 B ST-74 ST-32 Disease  United Kingdom (1985) AE002098 
α14 cnl
c 
ST-53 ST-53 Carried Bavaria (1999-2000) AM889136 
α153 29E ST-60 ST-60 Carried
d
 Bavaria (1999-2000) AM889137
 
α275 W135 ST-22 ST-22 Carried
d




 Sequence Type 
b 
Clonal Complex  
c
 Capsule null locus (Claus et al., 2002) 
d
 The isolates studied here are taken from asymptomatic individuals (Claus et al., 2005).  Different isolates of this 
serogroup and ST combination have been shown to cause a small percentage of meningococcal disease in Bavaria 
(Schoen et al., 2008). 
 
 
TABLE 6.2.  New N. meningitidis genomes recently characterized.  These genomes are reported in their final 
form in (Kislyuk et al., 2010). 





82 2.20 2108 
M10699 Oregon 
May 2003 
40 2.18 1978 
M15141 New York City 
Aug 2006 
50 2.28 2141 
M9261 Burkina Faso 
Apr 2002 
79 2.21 2261 
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Figure 6.1.  Disease associated versus carried isolate genome discriminating SNPs.
(A) Genome sequence alignment between disease associated (
presence of SNPs (gray arrows).  An example of a disease associated versus carried genome discriminating SNP is 
highlighted.  (B) A concatenated genome map of M13220.  The outer ring shows all genes, w
black and others in blue.  The inner ring shows the locations of SNPs.  Continued on the next page.  
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Figure 6.1 (continued).  Disease associated versus carried isolate genome discriminating SNPs.











PHYLOGENETIC ANALYSIS   
Whole genome sequence alignments were used to calculate nucleotide p-distances between 
N. meningitidis isolate genomes, and the distances were used to reconstruct an N. meningitidis 
phylogeny with the Neighbor-joining algorithm (Saitou & Nei, 1987) implemented in the 
program MEGA 4 (Kumar et al., 2008).  The same approach was used to reconstruct an N. 
meningitidis phylogeny based on a concatenated nucleotide sequence alignment of the 7 
multilocus sequence typing (MLST) loci: abcZ, adk, aroE, fumC, gdh, pdhC, and pgm (Holmes et 
al., 1999; Maiden et al., 1998).  1,000 bootstrap replicates of the MLST alignment were used to 
evaluate the confidence of the phylogeny.  
FIXATION INDEX (FST) ANALYSIS 
The FST statistic (Hudson et al., 1992) was used as a measure of the genetic differentiation 
between groups of N. meningitidis genomes.  FST was measured using the pairwise nucleotide p-
distances calculated from the N. meningitidis whole genome alignment.  Disease associated and 
carried isolate groups were used to compute the average within group genome p-distance (





∏−1 .  Simulation was used to compute a background distribution of FST 
values that could be expected given the levels of nucleotide variation among all genomes.  To do 
this, N. meningitidis genomes were randomly assigned to either the disease associated (n=8) or 
carried (n=3) groups and FST was re-calculated based on the random groups.  This was repeated 
10,000 times to yield a null frequency distribution of expected FST values.     
BAYESIAN CLUSTERING METHOD 
We used a Bayesian method implemented by the program STRUCTURE version 2.3.1 to 




variation (i.e. the structure) among the N. meningitidis genomes analyzed here (Pritchard et al., 
2000).  STRUCTURE was run with K=1, 2, 3, 4, and 5 groups.  For each K, the burn-in and run 
length parameter values were set to 50,000 each. 
GENOMIC AND FUNCTIONAL CHARACTERISTICS OF DISCRIMINATING SNPS 
Discriminating SNPs were mapped to N. meningitidis gene locations – either internal to or 
within 1kb of the coding sequence.  The resulting set of SNP genes (proteins) was then 
evaluated for statistically significant enrichment for a variety of functional characteristics 
including gene ontology (GO) annotations, the presence of a signal peptide, identity as a 
lipoprotein, horizontal transfer, subcellular location, and identity as a putative virulence factor.  
GO annotations were taken from the InterProScan database (Zdobnov & Apweiler, 2001).  The 
presence of signal peptides were inferred using the SignalP program (Emanuelsson et al., 2007).  
Lipoprotein status was inferred using the LipoP program (Juncker et al., 2003).  The horizontal 
transfer status of genes were inferred using a combination of three programs: BLAST (Altschul et 
al., 1997), CodonO (Angellotti et al., 2007) and AlienHunter (Vernikos & Parkhill, 2006), along 
with an analysis of GC-content.  Genes were called as putative virulence factors based on the 
Virulence Factors Database (VFDB) (Chen et al., 2005; Yang et al., 2008).  SNP genes were 
evaluated for statistical over-representation for each functional characteristic using the 
hypergeometric test implement in the program GeneMerge (Castillo-Davis & Hartl, 2003).  The 
hypergeometric test in this study gives the probability P of selecting r genes with a functional 
characteristic in the set of SNP genes k from an overall set of genes in the genome n, where p is 
the proportion of r genes in the population and sampling is without replacement (Equation 6.1).  
SNP genes found to encode significantly over-represented functions were further evaluated 




(http://nbase.biology.gatech.edu), NCBI’s RefSeq database (Pruitt et al., 2007), and the 
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RESULTS AND DISCUSSION 
COMPARATIVE GENOMIC SEQUENCE ANALYSIS OF N. MENINGITIDIS 
We hypothesize that SNPs can be used as markers that distinguish sets of disease associated 
versus carried genomes of N. meningitidis.  To test this hypothesis, and to search for potential 
genomic influences on virulence, we performed comparative sequence analysis of 11 isolates of 
N. meningitidis with completely sequenced genomes: 8 disease associated isolates from 
individuals with meningococcal disease and 3 carried isolates from asymptomatic individuals 
(Table 6.1).  The 4 previously published disease associated genomes are taken from a series of 
individual genome projects and represent the most common disease associated N. meningitidis 
serogroups : A, B, and C (Bentley et al., 2007; Parkhill et al., 2000; Peng et al., 2008; Tettelin et 
al., 2000).  The 3 previously published carried genomes were reported in 2008 as part of a 
comparative analysis of disease associated and asymptomatically carried N. meningitidis 
genomes that focused on differences in the presence and absence of virulence factor genes 
between the two groups (Schoen et al., 2008).  Although these three isolates were taken from 
asymptomatic individuals during a carriage study (Claus et al., 2005), other isolates of this 
serogroup and ST combination have been shown to cause a small percentage of meningococcal 




additional disease associated genomes of N. meningitidis that cover serogroups A, B and C and 
also include the first reported disease associated W135 serogroup genome sequence (Kislyuk et 
al., 2010).  The W135 isolate characterized here was isolated in Burkina Faso and was the cause 
of a major outbreak of bacterial meningitis at the 2000 Hajj (Dull et al., 2005; Lingappa et al., 
2003; Mayer et al., 2002).    
The N. meningitidis genomes were characterized via pyrosequencing using either a single or 
a half run on the Roche 454 instrument (Table 6.2).  The number of reads produced in the 4 
experiments ranged from 197,000-605,000, and the average read lengths were 105-245 base 
pairs.  Altogether, these data yielded 47.6-94.3 million bases per genome amounting to 20-40x 
coverage for the ~2.2 megabase N. meningitidis genomes.  We developed customized genome 
assembly, gene prediction and functional annotation pipelines to analyze these data (Kislyuk et 
al., 2010).  Our genome assembly procedure resulted in an order-of-magnitude decrease in the 
number of contigs produced by the Newbler assembler that ships with the 454 platform.  There 
are 38-82 contigs that cover 2.18-2.28 megabases of the 4 genomes.  We annotated 1978-2261 
genes including protein coding genes, non-coding RNAs and insertion sequences.  All 4 of the 
new genomes reported here, along with custom annotations and tools for searching and 







Figure 6.2.  Expected versus observed number of discriminating SNPs.  The N. meningitidis genome 
sequence alignment was simulated to yield a null distribution of the expected number of 
discriminating SNPs given the background variation.  The expected distribution is compared to 






SINGLE NUCLEOTIDE POLYMORPHISMS DISCRIMINATE BETWEEN DISEASE 
ASSOCIATED AND CARRIED GENOMES OF N. MENINGITIDIS 
Previous comparative genomic sequence analyses of disease associated versus carried 
isolates of N. meningitidis failed to turn up evidence of obvious genomic differences between 
the two groups based on the presence or absence of any particular genes.  In order to evaluate 
the genomic basis of the difference between disease associated and carried genomes here, we 
focused our analysis on differences at the level of individual nucleotide variation.  To do this, we 
compared genomic sequences of 8 disease associated and 3 carried isolates of N. meningitidis 
(Table 6.1).  Whole genome sequences of the N. meningitidis isolates were aligned as described 
in the Materials and Methods.  There are 69 long orthologous regions (Local Collinear Blocks) 
conserved among all 11 genomes, and the total length of the N. meningitidis genome sequence 
alignment is 1,140,825 positions, 841,520 of which are absolutely conserved.  
We identified aligned positions that show variation among genomes of N. meningitidis as 
single nucleotide polymorphisms (SNPs).  These SNPs include positions with insertion/deletion 
(i.e. alignment gap) variation among genomes.  There are a total of 299,305 SNPs in the whole 
genome N. meningitidis sequence alignment.  We characterized SNPs that discriminate between 
the genomes of disease associated versus carried isolates of N. meningitidis as those with 
mutually exclusive nucleotide patterns, including gap characters, between the two sets of 
sequences (Figure 6.1A).  There are 801 such discriminating SNPs, and they are distributed 
across the entire N. meningitidis genome (Figure 6.1B).  Discriminating SNPs were associated 
with individual N. meningitidis genes if they were found in the coding region or within 1 kb of a 
gene.  The frequency distribution of discriminating SNPs per gene shows that the majority of 
SNP genes are associated with only one, or very few, discriminating SNPs (Figure 6.1C).  Taken 
together, the genomic and frequency distributions of discriminating SNPs indicate that there is 




The disease associated versus carried isolate discriminating SNPs represent a catalog of 
individual nucleotide variation with potential implications for understanding the genomic basis 
of virulence in N. meningitidis.  However, this study covers a limited set of genomes, and it is 
likely that when additional or different sets of genome sequences are compared, distinct sets of 
discriminating SNPs will be observed.  Furthermore, with respect to the sequence data analyzed 
here, it is possible that we observe this number of discriminating SNPs (801) simply by chance 
alone given the large number of SNP positions found in the whole genome alignment analyzed 
here (299,305).  We performed a simulation analysis to evaluate the probability of observing 
801 discriminating SNP positions by chance alone given the background sequence variation 
among the aligned genomes.  To do this, the isolate identities of the aligned genomes were 
randomly permuted 10,000 times, and for each permutation, a number of discriminating SNPs 
over the permuted alignment was computed.  This procedure resulted in a null distribution of 
discriminating SNP counts, parameterized against the actual background variation, against 
which we compare our observed value (Figure 6.2).  The value of the observed number of 
discriminating SNPs falls far outside of the range of the entire set of simulated values.  
Accordingly, the observed number of discriminating SNPs is significantly greater than can be 
expected by chance alone given the background variation among the genomes of N. 
meningitidis studied here (z=9.4, P=5.9e-21 z-test; or P<10e-4 based on the simulation). 
DISCRIMINATING POLYMORPHISMS REFLECT PHENOTYPE RATHER THAN 
SHARED EVOLUTIONARY HISTORY. 
It is clear that there are many more SNPs that discriminate between the disease associated 
versus carried genomes of N. meningitidis analyzed here than can be expected by chance alone.  
While these SNP data are suggestive of genomic differences with phenotypic relevance for 
virulence, they may also be attributed to shared evolutionary history.  In other words, the 




isolates analyzed here are more closely related to each other than to the carried isolates and 
vice versa.  If this is indeed the case, then the overall nucleotide sequence variation observed 
here should partition the disease associated versus carried isolates into two discrete groups of 
related genomes.  We evaluated how N. meningitidis genome sequence variation is partitioned 
among the disease associated versus carried isolates studied here in several different ways: 1) 
using phylogenetic analyses to infer the evolutionary history of the genomes, 2) using a standard 
population genetic measure – the Fixation index (FST) – to evaluate how nucleotide variation is 
partitioned within and between the disease associated versus carried groups and 3) using naive 
Bayesian clustering of the observed SNP variation. 
We reconstructed the phylogenies of the N. meningitidis genomes analyzed here in order to 
assess their evolutionary relationships.  Specifically, we sought to evaluate whether the disease 
associated and carried genomes form distinct phylogenetic groups, each of which shares a 
unique common ancestor (i.e. monophyletic clades).  To do this, we first aligned the seven 
house-keeping loci used for multi-locus sequence typing (MLST) (Holmes et al., 1999; Maiden et 
al., 1998) among the 11 genomes analyzed here and reconstructed a phylogeny based on the 
concatenated alignment (Figure 6.3A).  The MLST sequence based phylogeny groups N. 
meningitidis genomes faithfully according to their sequence type (ST) and serogroup.  For 
instance, all 3 ST-11 genomes (FAM18, M15141 & M9261) have absolutely identical MLST loci 
sequences, and the serogroup B genomes (M10699 & MC58) group together.  The most 
important feature of this tree is the fact that the disease associated and carried isolates do not 
form separate and distinct monophyletic groups.  In fact, disease associated and carriage 
genomes are grouped together on this tree with high bootstrap support.  This finding indicates 
that the large number of disease associated versus carried isolate discriminating SNPs is not 





Figure 6.3. Phylogenetic analysis of disease associated and carried N. meningitidis isolate genomes.  Disease 
associated genomes are shown in red and carried genomes are in blue.  (A) A tree based on an 
alignment of the multilocus sequence typing loci: abcZ, adk, aroE, fumC, gdh, pdhC, and pgm 
(Holmes et al., 1999; Maiden et al., 1998).  (B) A tree based on a whole genome alignment.  
 
 
In attempt to gain more resolution for phylogenetic analysis, pairwise distances computed 
from the entire whole genome alignment were used (Figure 6.3B).  This version of the phylogeny 
is slightly different with respect to some of the less supported internal branches, but disease 
associated and carried genomes still do not form distinct mutually exclusive evolutionary 
groups.  On this tree, the carried genomes represent basal evolutionary lineages that are nested 
in between more derived lineages made up of disease associated genomes that are closely 




DISTRIBUTION OF SNP VARIATION AMONG N. MENINGITIDIS GENOMES 
In addition to phylogenetic analysis, we directly evaluated how SNP variation is distributed 
within and between disease associated versus carried genomes using a population genetic 
measure – the Fixation index (FST).  FST is a population differentiation measure that is based on 
polymorphism data; it measures the difference of between population variation from within 
population variation.  High values of FST (close to 1) indicate that polymorphisms tend to 
segregate between rather than within groups and reveal highly differentiated populations.  
Using the SNP variation data in the whole genome sequence alignment, we measured FST taking 
the disease associated versus carried groups of genomes as two putative populations (Figure 
6.4).  FST for disease associated versus carriage genomes is low (0.047) and statistically 
indistinguishable from a null distribution of FST values calculated using a simulation procedure 
similar to that described for the discriminating SNP analysis (z=0.5, P=0.6 z-test; or P=0.3 based 
on the simulation).  In other words, the polymorphism data based on the whole genome 
alignment do not provide evidence for population subdivision between disease associated and 
carried genomes of N. meningitidis as an explanation for the excess of observed discriminating 






Figure 6.4.  Differentiation of SNPs within and between grouped disease associated and carried N. meningitidis 
genomes based on the fixation index (FST).  The N. meningitidis genome sequence alignment was 
simulated to yield a null distribution of the expected range of FST values.  The expected FST range 






We also used a naïve Bayesian classification approach to partition SNP variation among the 
N. meningitidis genomes studied here using K-means clustering (Figure D.1).  This approach was 
implemented with the program STRUCTURE in order to address two questions: 1) What is the 
optimal value of K?  In other words how many genome groups do the SNP data indicate? and 2) 
Are disease associated versus carried genomes segregated into distinct groups based on the SNP 
data.  Based on a user defined value of K, STRUCTURE assess the statistical likelihood of 
observing the data given K and assigns individual SNPs into each group.  For any given genome, 
the fraction of SNPs in each group can then be ascertained.  This allows for a determination of 
the extent to which a given genome faithfully maps to one group or the other.  The optimal 
value of K according to this analysis is 3, not 2 as may be expected if disease associated and 
carried genomes formed distinct groups (Figure D.1A).  In addition, the SNP variation at K=3 
does not cleanly partition among individual genomes (Figure D.1B).  This result is consistent with 
a high level of recombination among N. meningitidis strains and is indicative of reticulate 
evolution and/or shared polymorphisms.  This is particularly true for the carried isolate 
genomes, which appear to have the most mixed ancestry in terms of the three SNP clusters.  
Disease associated genomes are less hybrid in general with respect to SNP polymorphism, and 
there are 5 disease associated isolates with SNPs that segregate almost perfectly into 1 of 2 
clusters.  Apparently, there have been abundant opportunities for genetic exchange subsequent 
to the divergence of these genomes and specific nucleotide variants acquired via recombination 
may be important markers for virulence. 
ASSOCIATION OF DISCRIMINATING SNPS WITH N. MENINGITIDIS GENES 
Disease associated versus carried genome discriminating SNPs were associated with genes if 
they were found either within or proximal to coding sequences (Table 6.3).  A total of 527 




‘SNP genes’.  One-hundred eighty-three of these discriminating SNPs map to gene-proximal non-
coding sequences, and 344 map to coding sequences. 
The 344 coding sequence discriminating SNPs were classified as either non-synonymous or 
synonymous based on whether or not they correspond to differences in encoded amino acid 
sequences between disease associated versus carried genomes.  There are 319 (92.7%) non-
synonymous discriminating SNPs compared to only 25 (7.3%) synonymous SNPs.  Since ~74.3% 
of all possible coding sequence substitutions are non-synonymous (Nei & Gojobori, 1986), these 
data indicate a statistically significant excess of non-synonymous substitutions among the 
coding sequence discriminating SNPs (χ2=60.6, df=1, P=7e-15).  The fact that coding sequence 
discriminating SNPs are more likely to result in changes at the level of protein sequence is 
consistent with the notion that these positions contribute to phenotypic differences between 
disease associated versus carried genomes.  Below, we explore the possible functional 





TABLE 6.3.  Genomic features of discriminating SNPs. 
Discriminating SNP class Count 
All  801 
Non-genic  274 
Gene associated 527 
Non-coding gene associated 183 
Coding sequence gene associated 344 
Non-synonymous coding sequence 319 
Synonymous coding sequence 25 
 
 
FUNCTIONAL ANALYSIS OF N. MENINGITIDIS DISCRIMINATING SNP GENES  
The SNP genes (proteins) were evaluated with respect to a wide variety of functional 
characteristics to determine if they are enriched for any particular functions or features that 
may be related to virulence.  The SNP genes were not found to be enriched for function at the 
cell periphery (i.e. signal peptides or lipoproteins), horizontally transferred genes or putative 
virulence factors.  However, the SNP genes were found to be enriched for 48 specific gene 
ontology (GO) functional annotations (Table 6.4).  Many of the enriched SNP genes span 
multiple functions due to the GO hierarchy; there are a total of 45 SNP genes among the 
overrepresented functional categories (Table 6.5).  Of the 45 genes with overrepresented 
functions, 10 are most closely related to virulence and we explore the potential functional 
relevance of these SNP genes below.  These 10 SNP genes are grouped into three distinct 
categories: “oxidoreductases,” “cell wall,” and “immune system evasion and other proteases” 
and represent a potential list of prioritized targets for future experimental interrogation based 





TABLE 6.4. Overrepresented functions and categories in SNP genes as compared to all genes in M13220.  











GO:0006596 polyamine biosynthetic 
process 
2 2 0.0028 
GO:0006595 polyamine metabolic 
process 
2 2 0.0028 
GO:0044403 symbiosis, encompassing 
mutualism through 
parasitism 
2 2 0.0028 
GO:0009405 pathogenesis 2 2 0.0028 
GO:0044419 interspecies interaction 
between organisms 
2 2 0.0028 
GO:0009065 glutamine family amino 
acid catabolic process 
2 2 0.0028 
GO:0006575 cellular amino acid 
derivative metabolic 
process 
14 4 0.0052 
GO:0006519 cellular amino acid and 
derivative metabolic 
process 
126 14 0.0061 
GO:0006576 biogenic amine metabolic 
process 
8 3 0.0069 
GO:0045454 cell redox homeostasis 18 4 0.0134 
GO:0042398 cellular amino acid 
derivative biosynthetic 
process 
10 3 0.0137 
GO:0019725 cellular homeostasis 20 4 0.0195 
GO:0006520 cellular amino acid 
metabolic process 
118 12 0.0213 
GO:0044106 cellular amine metabolic 
process 
118 12 0.0213 
GO:0042401 biogenic amine 
biosynthetic process 
5 2 0.0256 
GO:0016744 transferase activity, 
transferring aldehyde or 
ketonic groups 
5 2 0.0256 
GO:0051704 multi-organism process 5 2 0.0256 
GO:0009308 amine metabolic process 137 13 0.0283 
GO:0009056 catabolic process 96 10 0.0299 
GO:0043436 oxoacid metabolic 
process 
153 14 0.0307 
GO:0019752 carboxylic acid metabolic 
process 
153 14 0.0307 
GO:0030170 pyridoxal phosphate 
binding 
23 4 0.0314 
GO:0005496 steroid binding 23 4 0.0314 
GO:0070279 vitamin B6 binding 23 4 0.0314 
GO:0006082 organic acid metabolic 
process 
156 14 0.0355 






Table 6.4 (continued) 
GO:0009063 cellular amino acid 
catabolic process 
6 2 0.0371 
GO:0046395 carboxylic acid catabolic 
process 
6 2 0.0371 
GO:0016054 organic acid catabolic 
process 
6 2 0.0371 
GO:0009310 amine catabolic process 6 2 0.0371 
GO:0042180 cellular ketone metabolic 
process 
157 14 0.0373 
GO:0042592 homeostatic process 25 4 0.0414 
GO:0004527 exonuclease activity 15 3 0.0426 
GO:0009057 macromolecule catabolic 
process 
75 8 0.0443 
GO:0044248 cellular catabolic process 38 5 0.0494 
GO:0016796 exonuclease activity, 




7 2 0.0501 
GO:0043648 dicarboxylic acid 
metabolic process 
16 3 0.0504 
GO:0043603 cellular amide metabolic 
process 
16 3 0.0504 
GO:0032559 adenyl ribonucleotide 
binding 
165 14 0.0534 
GO:0005524 ATP binding 165 14 0.0534 
GO:0016667 oxidoreductase activity, 
acting on sulfur group of 
donors 
17 3 0.0589 
GO:0033554 cellular response to stress 40 5 0.0595 
GO:0030554 adenyl nucleotide binding 184 15 0.0620 
GO:0001883 purine nucleoside binding 184 15 0.0620 
GO:0001882 nucleoside binding 185 15 0.0644 
GO:0044270 nitrogen compound 
catabolic process 
8 2 0.0645 
GO:0051716 cellular response to 
stimulus 
41 5 0.0650 
GO:0004175 endopeptidase activity 29 4 0.0660 
a
 Category, as determined by comparing with GO 
b
 Number of genes in the genome belonging to this category (2108 total genes in the genome) 
c
 Number of SNP genes belonging to this category (113 total SNP genes) 
d























































































1 1 0 0 0 
a 
If it is defined, the consensus
 
gene name of the homolog found in strains Z2491/MC58/FAM18 
b
If defined, the locus tag of the homologous gene in strains Z2491/MC58/FAM18 
c
Total number of gene associated SNPs 
d
Number of SNPs found flanking the coding sequence of the gene 
e
Number of SNPs found within the coding sequence 
f
Number of nonsynonymous SNPs within the coding sequence 
g
Number of synonymous SNPs within the coding sequence 
h





Oxidoreductases.  The locus with homology to NMA0253/NMB0006/NMC2144 codes for a 
thioreductase with homology to the tlpA gene, which was characterized in N. gonorrhoeae 
(Achard et al., 2009).  While it is possible that TlpA homolog could play a role in pilin disulfide 
bond reduction, it has been speculated that it has a role in ameliorating oxidative stress from 
lysosomes and therefore promotes intracellular survival.  Another SNP gene product, DsbA1, is a 
lipoprotein that oxidizes sulfide bonds to create disulfide bonds, and it gets its oxidizing power 
from the electron transport chain (Tinsley et al., 2004).  Incidentally, there are several other SNP 
genes implicated in the pathways around the electron transport chain including those with the 
GO accession GO:0016651 whose function is “oxidoreductase activity, acting on NADH or 
NADPH” (File D.1). 
That both dsbA and the tlpA homolog are SNP genes with overrepresented functions may 
indicate that disulfide bonds are highly regulated in disease associated genomes of N. 
meningitidis.  High regulation would be especially pertinent given that certain pili require 
disulfide bond formation for their functions, especially PilE and PilQ, both of which are involved 
in the formation of type IV pili (Tinsley et al., 2004; Vivian et al., 2009).  Type IV pili are essential 
for intimate adhesion of capsulated meningococci to epithelial cells (Nassif et al., 1997).  At least 
one other SNP gene, pglA, codes for a protein with a function that may affect pili as well.  PglA is 
responsible for glycosylating a disaccharide on pilin, specifically at a serine residue (Power & 
Jennings, 2003).  At this site, PglA adds galactose (α1,3) to the disaccharide structure.  As a 
consequence of glycosylation, adherence to epithelial cells is debilitated (Marceau et al., 1998).  
Therefore one difference between disease associated and carried isolates could be variation in 
adherence to endothelial cells.  Consistent with this prediction, Joseph et al recently showed 
that adhesins are up-regulated in an invasive isolate of N. meningitidis (MC58) compared to a 




Cell Wall.  Although mviN is uncharacterized and is a putative gene in meningococcus, its 
products have been experimentally characterized in Escherichia coli and Salmonella 
typhimurium which are also gram-negative (Benjamin et al., 1991; Inoue et al., 2008).  A 
mutation in the functional S. typhimurium homolog of mviN renders an otherwise avirulent 
isolate virulent.  In E. coli, mviN has been shown to be essential for murein synthesis. 
Although ftsE is not directly involved in virulence, it is a transporter upstream of bolA which 
has been characterized in E. coli (Aldea et al., 1988).  Because it is only 61 nucleotides away from 
its neighbor and has the same transcriptional orientation, the bolA homolog is likely in the same 
operon as ftsE and under the same transcriptional regulation (Price et al., 2005).  BolA has been 
found to contribute to retaining normal cell morphology during stationary phase and in 
conditions of starvation (Santos et al., 2002).  Moreover, bolA regulates two penicillin binding 
proteins (PBPs) (PBP5 and PBP6).  PBPs are involved in the synthesis of murein and can be 
targets of β-lactam antibiotics.  Gene expression of bolA is more significant during exponential 
growth phase than stationary phase, which supports a hypothesized role – that bolA is critical 
for adaptation of cell morphology and cell wall composition to the growth conditions (Santos et 
al., 2002). 
Immune System Evasion and Other Proteases.  NhhA has a few purported functions including 
evading complement deposition and the resulting formation of the membrane attack complex 
(MAC) (Sjolinder et al., 2008) as well as autotransporter and adhesin activity (Scarselli et al., 
2006).  ∆nhhA mutants have reduced adherence to host cells and have more MAC deposition.  
Therefore NhhA is an adhesin and it contributes to meningococcal immune evasion. 
IgA1 protease (iga) was classically thought to cleave only IgA antibodies which are secreted 
at mucosal surfaces (e.g., the nasopharynx where meningococci can live) (Mistry & Stockley, 




limited, thereby decreasing agglutination and opsonophagocytosis.  Furthermore after IgA 
cleavage, the meningococcal cell surface can bind the remanant “self” Fabα fragments to mask 
the pathogen from the host immune system. 
While it still holds true that it cleaves IgA antibodies, IgA1 protease has other cleavage 
targets such as human chorionic gonadotropin, granulocyte-macrophage colony stimulating 
factor, the CD8 surface antigen of cytotoxic T lymphocytes, and LAMP1 (Mistry & Stockley, 
2006).  LAMP1 is a protein with a hypothetical structural function in lysosomes.  Not only has 
LAMP1 cleavage by IgA1 protease been shown to be a major factor in meningococcal 
pathogenesis (Hauck & Meyer, 1997; Lin et al., 1997), but some anecdotal evidence shows that 
LAMP1 cleavage helps the meningococcus escape from the phagosome (Hauck & Meyer, 1997). 
The gene lon, coding for Lon protease, has not been characterized in Neisseria but has been 
characterized in several other species including E. coli and Streptococcus pneumoniae (Ingmer & 
Brøndsted, 2009).  While a common cleavage sequence motif has not been found in its several 
targets, Lon is thought to target particular tertiary sequences.  These targets are likely to be in a 
nonglobular conformation with exposed hydrophobic patches or other specific structural motifs 
(Tsilibaris et al., 2006).  Lon permits intracellular survival of S. typhimurim through down-
regulation of Salmonella Pathogenicity Island I (SP-I) by cleaving an activator of SP-I (Boddicker 
& Jones, 2004).  Furthermore, Lon might increase resistance to oxidative stress especially in the 
cases of respiratory bursts from lymphocytes and also might increase resistance to low 
phagosomal pH (Takaya et al., 2003).  It is interesting to note that the gene with homology to 
oxidoreductase TlpA has the same function in increasing resistance to low phagosomal pH. 
The gene prlC is a homolog of opdA, found in E. coli and Salmonella enterica serovar 
Typhimurium, and is a metalloprotease (Conlin & Miller, 2000).  Not much is known about prlC, 




protein (HSP).  Many HSPs are induced by other environmental changes such as interaction with 
a eukaryotic host (Du et al., 2005).  Therefore prlC might aid in stress that is associated with 
interaction of the human host. 
DYNAMICS OF N. MENINGITIDIS COLONIZATION, CARRIAGE AND DISEASE  
The N. meningitidis genomes analyzed here were chosen based on the fact that the isolates 
originated from either diseased individuals, what we refer to as disease associated, or 
asymptomatic carriers, referred to here as carried isolates.  Thus, what we have observed in this 
analysis is essentially a snap-shot in time and place of a set of particular nucleotide variants that 
distinguish one group of N. meningitidis disease associated isolates from a group of carried 
isolates.  It must be noted, however, that in any individual, an invasive meningococcal disease 
case originates from an asymptomatic colonization state (Jolley et al., 2005; Meyers et al., 
2003).  Transition of the bacterium from a colonization to disease causing state may be 
accompanied by the acquisition of specific nucleotide variants; it may be dependent on the 
genetic background of the human host (Davila et al.) or other environmental factors, or it may 
be caused by some combination of these factors.  Thus, it is formally possible that the carried 
isolate genomes studied here could evolve rapidly to become invasive genomes that cause 
disease.  Indeed, we have shown here that disease associated and carried genomes do not form 
mutually exclusive evolutionary groups, consistent with repeated changes between these states 
over time (Figures 6.3 and 6.4).  Even closer evolutionary relationships between disease 
associated and carried isolates of N. meningitidis have been demonstrated elsewhere (Jolley et 
al., 2005).  Further consistent with the possibility of changing between disease associated and 
carried states, two out of the three carried isolates investigated here are members of a strain 
lineage that has been observed to cause a low percentage of the invasive disease in the 




factors necessitate that the discriminating SNPs and SNP genes identified here be treated with 
caution, since they could easily change depending on changes in the disease causing potential of 
the genomes in which they are found. 
CONCLUSION 
Because the presence or absence of genes alone does not determine meningococcal 
virulence (Bille et al., 2005; Hotopp et al., 2006; Perrin et al., 2002; Schoen et al., 2008; Snyder & 
Saunders, 2006; Stabler et al., 2005), we sought smaller differences in the form of SNPs between 
the genomes of 8 disease associated and 3 carried isolates of N. meningitidis.  We identified 801 
discriminating SNPs and the genes associated with 527 of them.  Of the 113 SNP genes 
identified, functional analysis indicates 10 as the most likely targets of further investigation 
based on their possible roles in virulence. 
In addition to the caveats described previously, it should be noted that the analyses 
performed here are limited by the relatively small number of complete genome sequences that 
were analyzed: 8 disease associated and 3 carried isolates.  Consequently, the particular set of 
discriminating SNPs characterized here, along with the list of SNP genes, will likely change as 
additional genome sequences are characterized and compared.  Thus, a more definitive 
understanding of genome-level differences between disease associated and carriage isolates of 
N. meningitidis will require the analysis of additional genomes.   
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THE GENOMIC BASIS OF A NONGROUPABLE NEISSERIA 
MENINGITIDIS ISOLATE 
ABSTRACT 
Neisseria meningitidis is a gram-negative bacterium that has the potential to cause acute 
diseases including meningitis and septicemia, but its spread can be reduced when its 
polysaccharide capsule type is inferred.  Its capsule can be classified into 12 different serogroups 
determined from the chemical composition of the capsule.  There is an antibody assay to infer 
the type of polysaccharide capsule and ideally, this assay will return exactly one positive result.  
However occasionally there are no or multiple reactions, i.e. nonagglutinating or 
polyagglutinating, respectively.  In these cases, the isolate is characterized as “nongroupable” 
(NG).  We have received and characterized an isolate (M16917) as NG-polyagglutinating.  To 
understand the origins of M16917, we performed multilocus sequence typing and whole 
genome profiling, and to better understand the origin of the capsule, we created a phylogeny of 
the capsule polymerase gene.  The results of these analyses are that the genome has its origins 
in serogroup C while the capsule is most related to serogroup B, thus strongly supporting a 
capsule switching event.  A three-way multiple sequence alignment between M16917 and 
representative serogroup B and C genomes was constructed and analyzed to uncover likely 
recombination breakpoints.  Four breakpoints were uncovered which flank two different 
recombination events.  These two cassettes are likely of serogroup B origin.  One breakpoint 
separates the capsule polymerase gene into serogroup B origin and serogroup C origin.  Previous 




capsule polymerase gene can alter its linkage specificity and 2) that certain mutations may cause 
a hybrid of two capsules.  Due to the recombination event in the M16917 capsule polymerase 
gene and in light of previous studies, it is possible that M16917 has a chimeric B/C polymerase.  
Future experimental characterization of the capsule structure could confirm this hypothesis. 
INTRODUCTION 
Neisseria meningitidis is a gram-negative bacterium that has the potential to cause sudden 
and acute diseases including meningitis and septicemia (Rosenstein et al., 2001).  It is highly 
competent and can exchange DNA through homologous recombination especially within its 
genus (Holmes et al., 1999; Jolley et al., 2005).  N. meningitidis is protected from host-mediated, 
complement-dependent bacteriolysis and phagocytosis by a polysaccharide capsule (Rosenstein 
et al., 2001) and is classified into 12 serogroups determined from the chemical composition of 
the capsule.  Distinct serogroup capsule compositions differ by either their particular sugar 
makeup or the linkages between sugars (Frosch & Vogel, 2006; Popovic & Ajello, 2003).  The 
most typically disease-associated serogroups are A, B, C, W135, and Y (Yazdankhah et al., 2004).  
Effective vaccines are available for the disease-associated serogroups A, C, W135, and Y (Bilukha 
& Rosenstein, 2005), whereas there is no protective vaccine specifically against the serogroup B 
capsule (Harrison et al., 2009). 
During an outbreak of meningococcal disease, determination of the particular serogroup 
provides information to public health officials as to whether or not vaccination can be used as a 
prevention measure.  Typically, if the serogroup of isolates from infected individuals can be 
characterized as one for which a vaccine exists, then the vaccine will be used prophylactically 
among close contacts of those individuals to help contain the outbreak.  This approach will only 




reasons, rapid identification of N. meningitidis capsule serogroups is a critical component of 
public health response to meningococcal disease.   
The chemical composition of the N. meningitidis polysaccharide capsule is classically 
inferred using the slide agglutination serogrouping assay (SASG) (Popovic et al., 1999; Popovic & 
Ajello, 2003).  The SASG assay reveals the capsule type with serogroup-specific antibodies that 
yield positive or negative reactions.  Ideally, exactly one reactivity will be positive per isolate, 
but occasionally there are multiple or no positive reactions.  In these cases, the isolate is 
characterized as “nongroupable” (NG).  Isolates that have multiple positive SASG results are 
referred to as NG-polyagglutinating.  Mothershed et al. introduced the serogroup-specific real-
time PCR assays (SGS-PCR) to help resolve NG SASG results (Mothershed et al., 2004).  The SGS-
PCR assay is a real-time PCR test using primers and probes specific to each serogroup.  The gene 
target for these assays is typically the gene that encodes capsule polymerase specific to each 
serogroup.  The CDC Meningitis Laboratory and other reference labs routinely perform both 
SASG and SGS-PCR to group isolates quickly and unambiguously.   
Despite the availability of these two assays for the characterization of N. meningitidis 
capsule serogroups, there remain instances of NG isolates and at times the SASG and SGS-PCR 
results do not agree.  Examination these NG isolates reveals three distinct classes: 
autoagglutinating, nonaggultinating and polyagglutinating.  Autoagglutinating isolates 
agglutinate in the saline control for the SASG assay via a mechanism unrelated to serogroup 
specificity.  Non-agglutinating isolates show no evidence of capsule expression and a number of 
such isolates have been genetically characterized.  This work showed that non-aggultination can 
result from a loss of capsule expression through point mutations and/or phase variation as well 
as partial or complete deletions of capsule operon sequences (Dolan-Livengood et al., 2003; 




more serogroup specific antisera.  At this time, the genetic basis of polyaggultination is less well 
understood.  Polyagglutination has been hypothesized to result from the expression of multiple 
capsule types, but has more often been attributed simply to the quality of the antisera reagents 
used in the SASG assay. 
In this report, we sought to characterize the genomic basis of an NG polyaggulitination 
result for a cerebrospinal fluid (CSF) isolate (M16917) taken from a patient with acute 
meningococcal disease.  To this end, we characterized and analyzed its complete genome 
sequence.  The genome was characterized using 454 pyrosequencing and the sequence was 
assembled and analyzed using the CG-Pipeline genome analysis software tool.  The M16917 
isolate was originally characterized as polyagglutinating based on the SASG assay and as 
serogroup B based on SGS-PCR.  Multi-locus sequencing typing (MLST) analysis of the M16917 
genome sequence as well as whole-genome sequence comparisons among multiple completely 
sequences strains of N. meningitidis revealed M16917 to be a member of the ST-11 sequence 
group despite the fact that ST-11 strains are typically associated with serogroup C capsule.  
Subsequent examination of the capsule locus revealed sequences with homology to both 
serogroup B and serogroup C strains of N. meningitidis.  Comparison with capsule loci from 
completely sequenced N. meningitidis B and C serogroup reference strains was used to reveal a 
complex chimeric B/C structure for the M16917 capsule locus by defining the strain origins of 
adjacent capsule locus subsequences along with the specific locations of recombination 
breakpoints.  The M16917 capsule locus results from two separate B/C recombination events 
and interestingly the capsule polymerase gene itself is a chimeric sequence containing both B 
and C type sequences.  These results underscore the complexity of genomic rearrangements 
that can occur at the capsule locus and suggest a specific genomic basis for the NG results from 





ISOLATION AND CHARACTERIZATION OF M16917 
The M16917 strain of N. meningitidis was isolated from the CSF of a 31 year old male with 
acute meningococcal disease.  M16917 was initially characterized with the SASG assay by the 
Illinois Department of Public Health in Chicago, Illinois.  M16917 was subsequently characterized 
by the CDC Meningitis Laboratory using both the SASG and SGS-PCR assays as previously 
described (Mothershed et al., 2004; Popovic & Ajello, 2003).  The genome sequence of M16917 
was characterized with 454 pyrosequencing by the CDC core facility as previously reported 
(Kislyuk et al., 2010).  To clarify a homopolymeric region in the adk locus, we performed Sanger 
sequencing as described at pubmlst.org (Jolley et al., 2004). 
GENOME BASED MLST ANALYSIS 
We employed a multilocus sequence typing (MLST) analysis, which characterizes bacterial 
isolates based on the alleles of seven highly conserved housekeeping genes (Holmes et al., 1999; 
Maiden et al., 1998), on the complete genome sequence of M16917.  The genome sequence 
was assembled de novo using the CG-Pipeline (v0.2.2) software tool (Kislyuk et al., 2010), and 
the assembly was compared to the PubMLST database of alleles for each of the seven 
housekeeping loci (Jolley et al., 2004) using BLAST (v2.2.17)(Altschul et al., 1997).  We 
determined the presence of an allele based on whether the best hit of the BLAST analysis had 
100 percent identity, with no gaps or mismatches, to that allele as well as an alignment length 
equal to the full length of the allele.  The concatenation of all seven alleles yields a sequence 
type (ST) which ordinarily belongs to a family of STs called a clonal complex (CC).  
REFERENCE BASED ASSEMBLY 
We performed a reference based assembly of M16917 using Newbler (v2.0.00.20) against 




Z2492 (ST-4/serogroup A), and α275 (ST-22/serogroup W135) (Table 7.1).  The quality of each 
reference based assembly was evaluated based on a number of metrics: the number of large 
contigs produced, the number of bases assembled, N50 size, and average contig size (See Table 
7.2 for definitions).  The assembly with the best overall metrics was used for further analysis in 
this study. 
 
Table 7.1.  N. meningitidis reference genomes used in this study. 




  Accession  
FAM18  C  ST-11  ST-11  AM421808.1  
MC58  B  ST-74  ST-32  AE002098  
α275  W135  ST-22  ST-22  AM889138  






WHOLE GENOME PROFILING 
The relative quality scores from M16917 reference assembly against the previously 
characterized FAM18, MC58, Z2491 and α275 genomes were used in whole genome profiling to 
evaluate the most likely origin of the M16917 genome.  For each individual nucleotide position 
of the reference genome in these assemblies, a cumulative quality score taken from the 
Newbler output was recorded, and positions that were not mapped by any M16917 reads were 
counted as gaps with a score of 0.  These scores were averaged for non-overlapping 1000bp 
windows across the reference genomes.  The distributions of reference assembly average scores 





Table 7.2.  Mapping results.  A mapping of all 454 pyrosequencing reads of M16917 against these reference 
genomes produced several assembly statistics.  The reference genome with the best statistics is more closely related 
to the query genome M16917.  The best statistics are defined by a higher average quality, lower number of contigs, 
more bases mapped, larger average contig size, and larger N50.  The metrics with FAM18 are consistently better than 
other mapping results.  
 Average Quality
a 











Z2491 (A)  56.1±16.2 392  1.93 Mb  4969  8671  
MC58 (B)  54.3±17.8 428  1.94 Mb 4740  8713  
FAM18 (C)  58.4±15.1 179  2.09 Mb  12176  31630  
α275 (W135)  54.4±17.8 457  1.92 Mb  4160  6714  
a
The quality is given as a Phred score, q=-10log(p) where p is the probability of an incorrect base call. 
b
Large contigs are those greater than 500 bp. 
c
Mapped bases are those that were able to be aligned against the reference genome. 
d
N50 is a standard quality metric for genome assemblies that summarizes the length distribution of contigs. It 




Figure 7.1.  The M16917 trace data were mapped to each reference genome using Newbler.
bases, cumulative quality scores of every base that mapped to the reference assembly were calculated.  These 
cumulative quality scores were averaged together among the 
reference genome were given a quality score of zero.  Red scores indicate high quality mapping, and blue scores 
indicate low quality mapping.  Mapping against FAM18 shows the highest cumulative average qua
MC58 shows the lowest. 
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IDENTIFICATION OF THE CAPSULE LOCUS AND CAPSULE POLYMERASE GENE  
M16917 capsule locus sequence containing contigs were assembled de novo to avoid any 
biases that may be introduced by reference based assembly to one serogroup strain or another.  
De novo assembled contigs were then aligned to the N. meningitidis reference genomes MC58 
(serogroup B) and FAM18 (serogroup C) using the program wgVISTA (Frazer et al., 2004; Mayor 
et al., 2000).  Contigs that were visually confirmed to align to the capsule locus in either MC58 
or FAM18 were retained for subsequent analysis.  The identity of specific capsule locus genes, 
including the capsule polymerase gene used in the SGS-PCR assays, in these contigs was 
confirmed using BLAST.   
PHYLOGENETIC ANALYSIS 
Using MEGA (Tamura et al., 2007) we performed a multiple sequence alignment (MSA) and 
subsequent neighbor-joining tree of reference capsule polymerase genes (FAM18, MC58, α275, 
and Z2491) and the nongroupable M16917 corresponding putative region.  
IDENTIFICATION OF RECOMBINATION BREAK POINTS 
We conducted a three way MSA of the capsular regions spanning rfbA to tex (the 
boundaries of the capsule locus) using CLUSTALW 2.0.10 (Larkin et al., 2007).  Within the 
alignment, we defined an informative site as any polymorphic site in which the nucleotide on 
M16917 matches either that of MC58 or FAM18, but not both.  If the site on M16917 matched 
that of MC58 or FAM18, the position would be labeled as B or C, respectively.  Those 
polymorphic sites that did not meet this criterion were not considered informative.  A string of 
informative sites corresponding to serogroup classification was generated and is referred to as 
the informative string. 
We employed a sliding window fifty positions long across the informative string and 




nucleotides each.  Pseudocounts equal to one were used to initiate each cell in the contingency 
table to facilitate χ2 analysis.  Analyses were performed for each contingency table to yield a p 
value, which was then transformed to a –log(p) value.  In this analysis, a local maxima in the –
log(p) graph indicates a possible recombination breakpoint.  
RESULTS AND DISCUSSION 
M16917 ISOLATION AND CHARACTERIZATION 
In 2007, the Bacteriology Laboratory at The Illinois Department of Public Health, Chicago 
received an isolate of N. meningitidis cultured from the CSF of a 31 year old male with 
meningitis.  They characterized the isolate as NG polyagglutinating using the SASG assay and 
sent it to CDC Meningitis Laboratory, which designated it as M16917.  CDC performed the SASG 
and SGS-PCR assays, which resulted in NG polyagglutinating and serogroup B results, 
respectively.   
We characterized and analyzed the complete genome sequence of M16917 in an effort to 
try and better understand the genomic basis of the NG polyagglutination phenotype.  The 
genome of M16917 was sequenced using 454 pyrosequencing and assembled de novo using the 
CG-Pipeline genome analysis software tool (Kislyuk et al., 2010).  This assembly yielded 71 
contigs >500bp in length with a longest contig of 192,528bp and an N50 value of 53,150bp.  The 
total length of the genome was found to be 2,158,678bp and there are 2,337 predicted protein 
coding genes.  These results are consistent with a number of previous N. meningitidis genome 
sequence projects (Kislyuk et al., 2010).   
ORIGINS OF THE M16917 GENOME 
The origin of the M16917 genome sequence was evaluated using two approaches: a 
genome based MLST analysis and comparative whole genome profiling against N. meningitidis 




M16917 assembly using BLAST, and the sequences for these loci were then queried against the 
PubMLST database (Jolley et al., 2004).  This analysis resulted in an MLST profile of ST-11 for 
M16917.  ST-11 is commonly associated with serogroup C in the United States (Harrison et al., 
2010).  The CDC polyagglutination results did include a positive reaction with serogroup C 
antisera as well as reactivity with antisera from serogroups B, W135 and Y.  However, the 
genome based MLST result is inconsistent with the SGS-PCR assay that resulted in a serogroup B 
result.  
MLST is considered to be a reliable typing method in part because it utilizes seven loci 
spread across the N. meningitidis genome.  However, the complete genome sequence should 
provide additional information with respect to the strain origins of M16917.  Whole genome 
profiling of M16917 was performed using reference-based assembly against complete genome 
sequences representative of the four serogroups A, B, C and W135 (Tables 7.1 and 7.2).  At the 
time of this analysis, there was no complete serogroup Y genome sequence.  For each reference 
genome and for each corresponding reference nucleotide position, we ascertained the 
cumulative mapping quality score.  Gaps were given a quality score of zero.  Including gaps, the 
average quality score, q, was 56 ± 17 with a range of 0 to 64 where q=-10log(p), and where p is 
the probability of an incorrect base call.  With this method, more distant genomes will have 
more areas not covered by the reads of query genome M16917.  Fewer reads that map well to 
the reference genome will result in lower quality scores.  Consequently, a closely related 
genome will have a relatively high overall quality score while a more distant genome will have a 
relatively low overall quality score.  Whole genome profiling supports that M16917 is more 
closely related to the ST-11/serogroup C lineage, and is least related to the ST-74/serogroup B 
lineage (Figure 7.1 and Table 7.2).  This result confirms the genome based MLST analysis and 




ORIGIN OF THE M16917 CAPSULE POLYMERASE GENE 
Taken together, the results of the MLST and the whole genome profiling analyses indicate 
that the genome of M16917 is most similar to serogroup C strains and most dissimilar to 
serogroup B.  Thus, the serogroup B result from the SGS-PCR assay could be based on a false 
positive PCR, or more intriguingly, could point to a capsule switching event from serogroup C to 
B.  Capsule switching occurs when a strain of N. meningitidis undergoes some kind of genetic 
alteration that results in the production of a capsule type that is more typical of a different 
serogroup.  The genetic basis of capsule switching was first identified by Swartley et al. who 
characterized an isolate that underwent a switch from serogroup B to C based on a horizontal 
gene transfer and subsequent recombination event at the capsule locus (Swartley et al., 1997).  
This particular transfer and recombination event introduced a serogroup C type capsule 
polymerase gene into a serogroup B genomic background.  Subsequent studies have implied 
probable capsule switching events based on distinct genetic versus antigenic similarities of 
different serogroups (Harrison et al., 2010; Tsang et al., 2005; Vogel et al., 2000).  
The SGS-PCR assay is based on serogroup specific primer sets designed to the capsule 
polymerase gene found in the synthesis operon of the capsule locus (Mothershed et al., 2004).  
To determine the origins of the M16917 capsule polymerase gene, we isolated its sequence 
from the genome assembly and compared it to reference capsule polymerase gene sequences 
from four different serogroups: A (strain Z2491), B (strain MC58), C (strain FAM18) and W135 
(strain α275).  Multiple sequence alignment and phylogenetic analysis of these sequences 
clearly indicates that the M16917 genome encodes a serogroup B type capsule polymerase gene 
(Figure 7.2).  This result confirms the results of the SGS-PCR assay, and when considered 
together with the serogroup C origin of the M16917 genomic background, points to a possible C 
 
 
to B capsule switching event.  However, it is not immediately apparent why such a capsule 
switching event would produce a NG polyaggultination result in the SASG assay.   
Figure 7.2. Phylogenetic analysis of the capsule polymerase gene.
representative capsule polymerase genes of M16917 and those from serogroups A, B, C, and W135.  T
polymerase gene of the nongroupable M16917 is most closely rel
 
ORIGIN OF THE M16197
While a number of different cases of capsule switching have previously been identified, the 
nature of the recombination events that underlie these switches have not been precisely 
characterized (Beddek et al.
due to the relatively limited amount of sequence information available in previous studies of 
capsule switching.  Given our characterization of the complete genome sequence of M16917, 
along with the availability of complete genome sequences for serogroup B and C strains, we 
reasoned that we would have sufficient data to 1) evaluate whether capsule switching based on 
recombination had in fact occurred and 2) if so more precisely define the location of 
recombination breakpoints in the M16917 sequence.  To do this, we constructed a three
sequence alignment of the capsule loci from the M16917, MC58 (serogroup B) and FAM1
(serogroup C) genomes, and evaluated the distribution of sequence similarity between the 
M16917 sequence and the serogroup specific B or C sequences along the locus.  
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  A phylogenetic tree was created with 
ated to that of MC58 (serogroup B).  
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Alignment positions where M16917 agreed exclusively with either MC58 (B) or FAM18 (C) 
were considered to be informative with respect to the genomic origins of the sequence and 
were recorded into a string of informative positions (Figure 7.3A).  A fifty-position sliding 
window was run along this string in single position steps, and the distribution of B and C 
informative positions in the upstream 25 positions versus the downstream 25 positions of each 
window was evaluated using 2 x 2 χ2 contingency table (Figure 7.3B).  Center window positions 
along the string that lead to the most disjoint B versus C distributions in the window, as 
measured by the significance level of the χ2 test, are considered to represent most likely points 
of recombination.  The χ2 test Significance levels (P-values) were transformed into a negative-
log-likelihood P-values to visually uncover local maxima.  These local maxima represent the most 
likely recombination break points.  Surprisingly, we uncovered four such sites that indicate the 
introduction of two serogroup B type genomic segments into the M16917 genome via 
recombination (Figure 7.3C).  We had initially expected to observe that a single recombination 
event underlies the capsule switch as has been previously assumed (Beddek et al., 2009; 
Swartley et al., 1997; Tsang et al., 2005).  These results suggest that the process of 
recombination leading to capsule switching is even more dynamic than had been imagined.  
However, it is worth noting that the average size of a recombination even in N. meningitidis was 
previously inferred to be 1.1 kb (Jolley et al., 2005), and the B serogroup specific sequence 
cassettes we observe are 1.9kb and 1.4kb in length consistent with this result.  Moreover, from 
the recombinant breakpoint analysis, it can be seen that one of the inferred breakpoints is 
contained within the capsule polymerase gene (synD in Figure 7.3C).  This would mean that the 
M16917 capsule polymerase gene, which is thought to be the primary determinant of the 




Figure 7.3.  Capsule locus analysis
(serogroups B, C, and NG, respectively). The informative string is constructed by categorizing each informative site as 
either B or C depending on whether the nucleotide at that position on M16917 matched that of MC58 or FAM18.  An 
informative site is formed by aligning M16917 capsule polymerase gene with reference capsule polymerase genes 
and recording the serogroup that M1691
informative string, 25 sites to the left and right were observed and classified as B or C into a contingency 2x2 table.  
For statistical purposes, a pseudocount of 1 was added to each c
performed, resulting in a probability value p.  This was then transformed using 
displayed is for the local maxima shown at position 4345. (C) A graph of 
derived from the contingency table as described in Fig. 
gray background that represent the informative string.  At the top is the color
informative string.  Local maxima on the graph, derived from low p values, represent the most likely recombination 
points, which delineate regions in the genome that originate from either serogroup B (red) or serogroup C (blue).  The 
mixture of serogroup B and C informative sites between 
of having lower selective pressure in the intergenic regions.
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CAPSULE SWITCHING AND NG POLYAGGULTINATION   
Moreover, it is clear that the capsule polymerase gene of the isolate under investigation 
contains one such statistically significant breakpoint, making it a chimera.  
The majority of the capsule polymerase gene, (synD in Figure 7.3C) and synC are included in 
the first cassette.  SynD completes the synthesis of the polysaccharide capsule by polymerizing 
the monomeric sugar created by SynC (Edwards et al., 1994; Warren & Blacklow, 1962).  The 
second cassette includes the two genes galE and ctrG, formally known as NMB0065 (Hobb et al., 
2010).  GalE sialylates lipooligosaccharide (LOS), and it has been shown that sialylation of LOS is 
indispensible for serum resistance for serogroup B N. meningitidis (Vogel et al., 1997).  CtrG 
functions with other proteins (CtrE, CtrF) as a chaperone in shuttling polysaccharide molecules 
to a transporter (comprised of CtrA-D), which then moves the polysaccharide to the surface to 
build the capsule. 
CAPSULE SWITCHING AND NG POLYAGGULTINATION   
Capsule switching has previously been implicated in the NG polyagglutination phenotype via 
changes to the capsule polymerase gene.  Capsule polymerase genes complete the synthesis of 
polysaccharide capsules by polymerizing the monomeric sugar units from which they are 
composed in a serogroup specific fashion (Table 7.3).  For example, the serogroup B type 
capsule polymerase SynD creates α2→8 linkages between sialic acid monomers to form the B 
capsule polysaccharide, whereas the C type capsule polymerase gene encodes SynE that creates 
a capsule with α2→9 sialic acid linkages (Frosch et al., 1989; Swartley et al., 1997; Swartley et 
al., 1998).  Steenbergen and Vimr experimentally demonstrated that the linkage specificity of 
identically composed Escherichia coli polysaccharide capsules could be changed from α2→8 to 




(Steenbergen & Vimr, 2003).  These results underscore the possibility that recombination events 
within capsule polymerase genes can lead to changes in capsule phenotpyes.    
 
Table 7.3.  Serogroup Capsule Type and Gene Target Names. 
Serogroup Capsule type Capsule polymerase gene
a 
Ref 
B (α2→8)- N-acetylneuraminic acid synDb 
siaD 
siaD of B 
siaDB 
(Frosch et al., 1989; 
Swartley et al., 1996) 
C (α2→9)- N-acetylneuraminic acid synEb 
siaD of C 
siaDC 
(Frosch et al., 1989; 





siaD of W135 
siaDW 
(Bhattacharjee et al., 





siaD of Y 
siaDY 
(Bhattacharjee et al., 
1976; Claus et al., 1997) 
a
Bold names are primary names.  Alternative names are given as unbolded.  
b
The synD and synE genes of serogroups B and C, respectively, are alleles and encode capsular polysaccharide 
polymerases that catalyze different linkages of sialic acid monomers (α2→8 linkage for serogroup B and α2→9 linkage 
for serogroup C). 
c
The synF and synG genes of serogroups Y and W135, respectively, are alleles and encode capsular 




While interesting and potentially relevant, the aforementioned results were obtained in a 
laboratory setting on an analogous experimental system.  In N. meningitidis, an actual isolate 
with a serogroup Y type genome was shown to be NG polyagglutinating by virtue of cross 
reactivity with both serogroup Y and W135 antisera (Tsang et al., 2008).  Amazingly, capsular 
structures produced by this strain were found to contain sialic acid units along with both 
glucose, which is a Y serogroup capsule specific sugar, and the W135 specific sugar and 




type features.  The capsule polymerase gene was found to be clearly more closely related to the 
Y type gene than to the W135 capsule polymerase but differed from the canonical Y type 
sequence by three non-synonymous point mutations.  These point mutations were apparently 
sufficient to produce a chimeric capsule and the resulting NG polyagglutinating phenotype.  
Considering the results of these two studies together with the results we report here, it may 
be possible that recombination leading to a chimeric capsule polymerase gene could also lead to 
a hybrid capsule and the kind of NG polyagglutination result seen for M19617.  Indeed, we 
found one of the inferred recombination breakpoints to be located within the capsule 
polymerase gene leading to a chimeric B/C polymerase (Figure 7.3C).  It is tempting to speculate 
that such a chimeric polymerase gene may encode proteins with hybrid α2→8 or α2→9 sialic 
acid linkage activity leading capsular structures with cross reactivity to both B and C antisera.  
Confirmation of this hypothesis would require experimental characterization of the capsule 
structure of the M16917 isolate.       
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This dissertation holds several chapters which have advanced the study of comparative 
genomics and epidemiology.  Chapter 2 describes the online suite of tools called MGIP that 
accompany MLST analysis.  Before MGIP, analysis of MLST data was very difficult and error-
prone.  Currently MGIP is being updated as indicated in chapter 3.  One important update is to 
be able to accommodate other organisms including influenza and its sequence typing method 
STaRS.  The interface for influenza is called InGen, and it has been showcased to U.S. labs that 
work with CDC and other health agencies.  In addition, InGen has been presented to Egypt for a 
possible way to survey influenza and it has also been presented in a meeting in China where it 
may be accepted by international reference labs.  InGen has a major advantage over other 
typing systems in that it will be used to gather influenza data in real time from participating 
typing institutions, thereby allowing CDC and other worldwide institutions to track influenza 
more quickly than ever. 
Chapters 4 and 5 discuss the CG-Pipeline and NBase.  These tools greatly facilitate the 
assembly, annotation, storage, visualization, and analyses of prokaryotic genomes.  These tools 
will be taken to the next level, for they are continuously being updated.  CG-Pipeline’s updates 
will be to include different kinds of sequence data; to increase its prediction capabilities and 
accuracy; to increase the level of annotations; and to provide some genome-wide statistics.  
NBase will be updated to accommodate the amounts of data that will be generated by CG-
Pipeline, which will be increased as whole-genome sequencing becomes more common and as 




increased.  There are many tools for a GBrowse-based system including SynView that would be 
quite useful in our comparative genomics database (Wang et al., 2006).  In essence, these tools 
CG-Pipeline and NBase are quite useful as they are now, but we have plans to make them as 
comprehensive as possible. 
In chapter 6, I asked a pressing question in meningococcal research: “What is the genomic 
basis of virulence in N. meningitidis?”  Although some isolates cause devastating disease, the 
great majority do not cause disease and live as harmless commensals in humans.  Scientists have 
wondered for almost a century what causes virulence in N. meningitidis and have been asking 
this question as it relates to its genome for the last ten years.  I compared several whole virulent 
and carried genomes of N. meningitidis to find several discriminating SNPs and associated genes 
that serve as markers for virulence or carriage.  These genes will be under further investigation 
of whether or not they can trigger meningococcal virulence.  I have come closer to answering 
this question than anyone ever has.   
In chapter 7, I asked another pressing question: “What causes nongroupability in N. 
meningitidis?”  Determining the serogroup of an isolate is important, as it aids in surveillance 
and in determining vaccination strategy.  When an isolate cannot be classified into any one 
group, it is considered nongroupable and hinders efforts to combat N. meningitidis.  I compared 
the genome and capsule locus of a nongroupable isolate against several reference genomes and 
found homologous recombination events that probably led to its nongroupability.  In addition, I 
created some algorithms to help in this investigation.  The first, which I call genome profiling, 
shows degrees of relatedness when comparing a query genome against other reference 
genomes.  The second shows exact recombination sites.  These sites had never been found 





This thesis reflects my point of view of bioinformatics as it applies to public health and 
Neisseria meningitidis.  I have developed important tools to fight this bacterium and have 
performed crucial analyses to aid in public health.  These tools and studies will be able to be 






APPENDIX A  
SUPPLEMENTARY INFORMATION FOR CHAPTER 2 
Table A.1.  Loci that MGIP can analyze by default.  
Locus Name
a  Descriptionb  Length (nts)c  
Standard MLST loci  
abcZ  putative ABC transporter  433  
adk_  adenylate kinase  465  
aroE  shikimate dehydrogenase  490  
fumC  fumarate hydratase  465  
gdh_  glucose-6-phosphate dehydrogenase  501  
pdhC  pyruvate dehydrogenase subunit  480  
pgm_  phosphoglucomutase  450  
Additional MGIP-specific loci  
fhb_  factor-H binding protein  *  
gna2132  unknown  *  
nadA  putative oligomeric coiled-coil adhesin  *  
opa  opacity porin protein  *  
porA  porin  *  
porB  porin  *  
fetA  iron-regulated outer membrane protein  *  
penA  penicillin-binding protein  402  
a
 Loci are given by their gene names.  
b
 Names/descriptions of the encoded proteins.  
c




 Table A.2.  Upload speeds for a set of trace files.  The average size of a set of trace files in our tests was 11 
megabytes (MB).  These times do not include processing time.  
Size (KB)  Speed (KB/second)  Label  Time (seconds) 
11,000 106  Internal Network 0.011 
11,000 104  T1 1.1 
11,000 2000 FIOS 5.5 
11,000 600 Cable 18.3 
11,000 400 DSL 27.5 












Figure A.1. The Strain Table.  The strain table shows the MLST profile for each strain or isolate that has been 
analyzed by an individual user.  (A) The strain table loads quickly because ST possibilities are not shown until the user 
makes a request by clicking on the "View ST Possibilities" link.  (B) When there are multiple possibilities, all are shown 
in a drop down menu.  When one of the possibilities is chosen, another request is made to the server to retrieve the 
ST and its allele components.  Alternatively, an icon above the table allows the user to load every strain's ST 
possibilities at once.  (C) One last notable item about the strain table is that it indicates novel STs when it encounters 






SUPPLEMENTARY INFORMATION FOR CHAPTER 4 
Optional parts of the assembly stage included manual gap joining curation for scaffolding in 
the absence of paired-end reads, and frameshift detection for homopolymer-induced 
frameshifts. 
The manual gap joining stage involved the layout of contigs according to their aligned 
position on the reference using the AMOS package and manual examination of each gap, 
adjacent contig alignments and reference annotation in the MAUVE visualization tool. We then 
recorded all gaps considered safe to join on the basis of this information into a gap fill 
specification file, which is a tabulated file in the format “contig 1 name, contig 1 end position, 
reference start position, gap length, reference end position, contig 2 name, contig 2 start 
position”, with one gap fill description per line. A script was then used to produce the final 
FASTA formatted output, with gaps filled with N (unknown nucleotides) by default, or optionally 
with sequence from the reference strain. 
The homopolymer-induced frameshift stage used the FSFind package from (Kislyuk et al., 
2009). Briefly, this package creates a GeneMark model of the genome, makes gene predictions, 
and then scans the genome for possible frameshift positions on the basis of ORF configuration 
and coding potential. Once the possible frameshift sites are identified, a putative translation of 
the protein possibly encoded by the broken gene is compared against a protein database 
(SwissProt by default). The predicted frameshift site is also scanned for adjacent homopolymers. 
A heuristic set of confidence score cutoffs is then used to provide a set of frameshift predictions 




used for either targeted re-sequencing or predictive correction using a supplied script. The 
output can be manually run through the gene prediction and annotation stages of the pipeline 
again. 
To demonstrate the overall accuracy of the prediction stage, we ran it on the genome of E. 
coli K12, one of the best-annotated bacterial genomes. Our stage was able to detect 95.7% of 
intact ORFs annotated as protein-coding, and exactly predict starts in 85.5% of those.  50% of 
the predictions that do report incorrect start codons report starts within 35 nt of the true start, 
and all reported starts are within 200 nt of the true start. 
The complete genome of Escherichia coli K12, accession number NC_000913.2, was 
downloaded from GenBank and its DNA sequence extracted into a FASTA file. The file was then 
given as input to the prediction component of the pipeline, which utilized the combination of de 
novo predictors GeneMark and Glimmer3.  We note that the validation on the E. coli genome 
was performed without the BLAST gene prediction component, because all accurately 
annotated E. coli genes and genes of close relatives are present in the SwissProt database, so 
using that component would have made the trial biased.  This is why the analysis proceeded 
with only the two de novo predictors, which impacted accuracy. 
GenBank-formatted output of the prediction component was tabulated to include only CDS 
sequence annotation boundaries.  The same procedure was done for the reference E. coli 
annotation from the original file.  Sequences with frameshifted and interrupted CDS (i.e. non-
intact ORFs) were omitted from the comparison due to lack of capability in our prediction 







SUPPLEMENTARY INFORMATION FOR CHAPTER 5 
Table C.1.  All genomes shown are included in the multiple sequence alignment and are present in NBase. 












M20918 Iowa, USA 2009 A Invasive 4789 5 N/A 
M13220 Philippines 2005 A Invasive 7 5 20519285 
M18575 Burkina Faso 2003 A Invasive 2859 5 20519285 
Z2491 Gambia 1983 A Invasive 4 4 10761919 
M17277 Maryland, USA 2006 NG Carriage 5916 41/44 N/A 
M16207 North Dakota, USA 2007 B Invasive 162 162 N/A 
M17094 Minnesota, USA 2008 B (C) Carriage 32 32 N/A 
MC58 Gloucester, UK 1985 B Invasive 74 32 10710307 
M10699 Oregon, USA 2003 B Invasive 32 32 20519285 
M5178 Oregon, USA 1998 B Invasive 32 32 20519285 
053442 Anhui province, China 2003 C Invasive 4821 4821 18031983 
8013 France 1989 C Invasive 177 18 19818133 
FAM18 North Carolina, USA 1980s C Invasive 11 11 17305430 
M15141 New York, USA 2006 C Invasive 11 11 20519285 
α14 Bavaria, Germany 1999-2000 NG-cnl Carriage 53 53 18305155 
M17062 Minnesota, USA 2008 NG Carriage 198 198 N/A 
M15293 Georgia, USA 2006 NG (B)
 
Invasive 32 32 20519285 
M16917 Illinois, USA 2007 NG
 
Invasive 11 11 N/A 
α153 Bavaria, Germany 1999-2000 29E Carriage 60 60 18305155 
α275 Bavaria, Germany 1999-2000 W135 Carriage 22 22 18305155 
M13519 New York, USA 2005 W135 (C) Invasive 11 11 N/A 
M17661 Michigan, USA 2008 W135 (C) Invasive 11 11 N/A 
M18774 Florida, USA 2009 W135 Invasive 11 11 N/A 
NM9261 Burkina Faso 2002 W135 Invasive 11 11 20519285 
M11791 New York, USA 2003 Y Invasive 23 23 N/A 
M14900 Oregon, USA 2006 Y Invasive 1625 23 N/A 






Table C.1 Continued 
a
 Origins are based on literature searches for each genome or based on unpublished notes at Centers for Disease 
Control and Prevention. 
b
 Serogroup.  Sgs are defined as a result of the SASG test, and if PCR had a differing result its resulting serogroup 
is in parentheses (Mothershed et al., 2004).  cnl: the capsule locus is nonexistent and no capsule is expressed.  
c
 Sequence Type (ST), Clonal Complex (CC). 
d




Figure C.1.  Uploading additional tracks.  The upload form, with the correct file format.










Figure D.1.  Partitioning of SNP variation among 
likelihood of the observed SNP data based on the number of clusters 
to each cluster (purple, teal and peach) are shown for invasive (red) and carried (blue) str
clonal complex, and serogroup is labeled. 
File D.1. All SNP genes.  
three reference genomes. 
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